Method for generation of multivalent bispecific antibody expressing cell by targeted integration of multiple expression cassettes in defined organization
By integrating multiple expression cassettes in predetermined configurations using RMCE, the method addresses the challenges of random integration in producing recombinant mammalian cells, achieving stable and efficient expression of trivalent bispecific antibodies.
Patent Information
- Application Number
- JP2024137673
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-06-19
- Filing Date
- 2024-08-19
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for producing recombinant mammalian cells expressing multivalent, multispecific antibodies face challenges such as random integration leading to unpredictable phenotypes, unstable expression, and inefficient production, requiring extensive screening and resulting in sequence divergence, especially when producing complex polypeptides.
The integration of multiple expression cassettes in specific and predetermined configurations into the mammalian cell genome using a dual recombinase-mediated cassette exchange (RMCE) reaction to stabilize and control the expression of trivalent bispecific antibodies, ensuring efficient production.
This method enables stable and efficient expression of trivalent bispecific antibodies, improving yield and reducing the need for extensive screening, while maintaining consistent expression ratios and reducing sequence divergence.
Smart Images

Figure 2024167256000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to the field of cell line engineering and polypeptide production. More precisely, recombinant mammalian cells obtained by a double recombinase-mediated cassette exchange reaction leading to the integration of specific expression cassette sequences into the genome of mammalian cells are reported herein. Said cells can be used in a method for producing multivalent, multispecific antibodies. [Background technology]
[0002] Background of the Invention Secreted glycosylated polypeptides, such as antibodies, are usually produced by recombinant expression in eukaryotic cells, either as stable or transient expression.
[0003] One strategy for generating recombinant cells that express an exogenous polypeptide of interest involves random integration of a nucleotide sequence encoding the polypeptide of interest, followed by selection and isolation steps. However, this approach has several drawbacks. First, functional integration of a nucleotide sequence into a cell's own genome is not only a rare event, but these rare events, given the randomness of where the nucleotide sequence is integrated, can result in a variety of phenotypes in gene expression and cell growth. Such mutations, known as "position effect mutations," are due, at least in part, to the complex gene regulatory networks present in eukaryotic cell genomes and the accessibility of specific genomic loci for integration and gene expression. Second, random integration strategies generally do not control the number of nucleotide sequence copies integrated into the cell's genome. In fact, gene amplification methods are often used to obtain high-producing cells. However, such gene amplification can also lead to undesirable cellular phenotypes, such as unstable cell growth and / or product expression. Third, due to the heterogeneity of integration loci inherent in the random integration process, screening thousands of cells after transfection to isolate recombinant cells exhibiting the desired expression level of the polypeptide of interest is time-consuming and labor-intensive. Even after isolating such cells, stable expression of the polypeptide of interest is not guaranteed, and further screening may be required to obtain stable, commercially available production cells. Fourth, polypeptides produced from cells obtained by random integration exhibit a high degree of sequence variability, which may be due in part to the mutagenicity of the selection agent used to select for high levels of polypeptide expression. Finally, the greater the complexity of the polypeptide to be produced, i.e., the greater the number of different polypeptides or polypeptide chains required to form the polypeptide of interest in cells, the more important it becomes to control the expression ratios of different polypeptides or polypeptide chains.Control of the expression rate is required to allow efficient expression, correct assembly, and successful secretion of the polypeptide of interest with high expression yields.
[0004] Targeted integration by recombinase-mediated cassette exchange (RMCE) is a method for specifically and efficiently directing foreign DNA into predetermined sites in the eukaryotic host genome (Turan et al., J. Mol. Biol. 407 (2011) 193-221 (Non-Patent Document 1)).
[0005] WO 2006 / 007850 discloses a production method using an anti-RhD recombinant polyclonal antibody and site-specific integration into the genome of an individual host cell.
[0006] Crawford, Y., et al. (Biotechnol. Prog. 29 (2013) 1307-1315 (Non-Patent Document 2)) reported that a combination of phiC31 integrase and CRE-Lox technologies was used to rapidly identify reliable hosts for targeted cell line development through limited genomic screening.
[0007] WO 2013 / 006142 (Patent Document 2) discloses a near-homogeneous population of genetically modified eukaryotic cells that have stably integrated into their genomes a donor cassette comprising a targeting nucleic acid site and a strong polyadenylation site operably linked to an isolated nucleic acid fragment comprising a selectable marker protein coding sequence, the isolated nucleic acid fragment being flanked by a first recombination site and a second, distinct recombination site.
[0008] WO 2018 / 162517 (Patent Document 3) discloses that large variations in expression yield and product quality were observed depending on i) the expression cassette sequence and ii) the distribution of the expression cassette among various expression vectors.
[0009] Tadauchi, T., et al. disclose the use of a controlled targeted integration cell line development approach to systematically examine what makes antibody expression difficult (Biotechnol. Prog. 35 (2019) No. 2, 1-11 (Non-Patent Document 3)).
[0010] WO 2016 / 079076 (Patent Document 4) discloses a T cell-activating bispecific antigen-binding molecule directed against FolR1 and CD3. Example 29 describes the production of a bispecific FolR1 / CD3-kappa-lambda antibody using transient transfection, with a plasmid ratio of three expression vectors of 1:1:1. Example 36 describes the preparation of DP47 GS TCB by co-transfecting HEK293-EBNA cells with the corresponding expression vectors at a ratio of 1:2:1:1 ("Vector heavy chain Fc (hole)":"Vector light chain":"Vector light chain CrossFab":"Vector heavy chain Fc (knob)-FabCrossFab").
[0011] WO 2014 / 033074 (Patent Document 5) discloses a blood-brain barrier shuttle. In Example 2, transient production of trivalent MAb31-scFab(8D3) is disclosed using three expression plasmids at an equimolar plasmid ratio during transfection.
[0012] WO 2017 / 184831 (Patent Document 6) purports to disclose a method for improving the site-specific integration and expression of recombinant proteins in eukaryotic cells, in particular the expression of antibodies, including bispecific antibodies, in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by using expression-enhancing loci. The data in this document are presented in an anonymized manner and therefore do not allow conclusions about what was actually done. When Cre recombinase was used, it was co-transfected on an additional plasmid, but this plasmid is not described with regard to its composition or origin.
[0013] Rajendra, Y., et al. disclose that a single quad vector is a simple yet effective alternative approach for the generation of stable CHO cell lines, which may accelerate cell line generation for clinical hetero-mAb therapy (Biotechnol. Prog. 33 (2017) 469-477 (Non-Patent Document 4)).
[0014] Gurumurthy, CB and Kent Lloyd, KC, have disclosed a mouse model for biomedical research (Dis. Mod. Mech. 12 (2019) (Non-Patent Document 5)). The inventors discuss how traditional gene targeting by homologous recombination in embryonic stem cells has been replaced by a more sophisticated method that allows allele-specific manipulation in the zygote.
[0015] Bahr, S., et al. disclosed the development of a platform expression system using targeted integration in Chinese hamster ovary cells (Proceedings of Cell Culture Engineering XVI, 2018 (Non-Patent Document 6)).
[0016] WO 2017 / 060144 (Patent Document 7) discloses a bispecific antibody with tetravalency for costimulatory TNF receptors. WO 2019 / 086497 (Patent Document 8) discloses combination therapy with targeted Ox40 agonists. [Prior art documents] [Patent documents]
[0017] [Patent Document 1] International Publication No. 2006 / 007850 [Patent Document 2] International Publication No. 2013 / 006142 [Patent Document 3] International Publication No. 2018 / 162517 [Patent Document 4] International Publication No. 2016 / 079076 [Patent Document 5] International Publication No. 2014 / 033074 [Patent Document 6] International Publication No. 2017 / 184831 [Patent Document 7] International Publication No. 2017 / 060144 [Patent Document 8] International Publication No. 2019 / 086497 [Non-patent literature]
[0018] [Non-Patent Document 1] Turan et al.,J.Mol.Biol.407(2011)193-221 [Non-patent document 2] Crawford, Y., et al. (Biotechnol.Prog.29(2013)1307-1315) [Non-patent document 3] Tadauchi, T., et al.(Biotechnol.Prog.35(2019)No.2,1-11) [Non-patent document 4] Rajendra,Y.,et al.(Biotechnol.Prog.33(2017)469-477) [Non-Patent Document 5] Gurumurthy, C.B. and Kent Lloyd, K.C. (Dis. Mod. Mech. 12 (2019)) [Non-patent document 6] Bahr, S., et al. (Proceedings of Cell Culture Engineering XVI, 2018) Summary of the Invention
[0019] Trivalent bispecific antibodies: This specification reports recombinant mammalian cells that express trivalent bispecific antibodies, particularly bivalent monospecific antibodies that contain an additional scFv or Fab fragment at the C-terminus of one of their heavy chains. Trivalent bispecific antibodies are heteromultimeric polypeptides that are not naturally expressed by the mammalian cells. More specifically, trivalent bispecific antibodies are heteromultimeric proteins consisting of four polypeptides: one light chain that is a full-length light chain, an additional light chain that is a domain-swapped light chain, one heavy chain that is a full-length heavy chain, and an additional heavy chain that is an extended heavy chain containing an additional domain-swapped heavy chain or light chain Fab fragment at the C-terminus. To achieve expression of trivalent bispecific antibodies, recombinant nucleic acids containing multiple different expression cassettes in specific and predetermined sequences are integrated into the genome of mammalian cells.
[0020] In particular, the methods of the present invention can be used to generate brain-shuttle antibodies, which may have a format such as that described in WO 2014 / 033074. These molecules can simultaneously bind to the human transferrin receptor (first specificity) and the target therapeutic antigen (second specificity) on cells of the blood-brain barrier, thereby inducing transport and therapeutic effect.
[0021] Also reported herein are methods for making recombinant mammalian cells that express trivalent bispecific antibodies and methods for producing trivalent bispecific antibodies using said recombinant mammalian cells.
[0022] In a preferred embodiment, the trivalent bispecific antibody comprises: a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; a first light chain comprising, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain Including, the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site; The first binding site specifically binds to the human transferrin receptor.
[0023] In a preferred embodiment, the trivalent bispecific antibody comprises: a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, the first heavy chain variable domain and a CH1 domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; a first light chain comprising, from N-terminus to C-terminus, a second light chain variable domain and a CH1 domain; and a second light chain comprising, from the N-terminus to the C-terminus, a second heavy chain variable domain and a CL domain Including, the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site; The first binding site specifically binds to the human transferrin receptor.
[0024] In a preferred embodiment, neither the first nor the second light chain of the trivalent bispecific antibody is a common or universal light chain.
[0025] The present invention is based, at least in part, on the discovery that the sequence of different expression cassettes required for expression of heteromultimeric trivalent bispecific antibodies, i.e., expression cassette configuration, affects the expression yield of trivalent bispecific antibodies (e.g., brain-shuttle antibodies) when integrated into the genome of mammalian cells.
[0026] The present invention is based, at least in part, on the discovery that efficient recombinant expression and production of trivalent bispecific antibodies (e.g., brain-shuttle antibodies) can be achieved by integrating nucleic acids encoding heteromultimeric trivalent bispecific antibodies with specific expression cassette configurations into the genome of mammalian cells.
[0027] It has been found that a given expression cassette sequence can be advantageously integrated into the genome of a mammalian cell by a dual recombinase-mediated cassette exchange reaction.
[0028] One embodiment according to the present invention is a method for producing a trivalent bispecific antibody, comprising: a) culturing mammalian cells containing deoxyribonucleic acid encoding the trivalent bispecific antibody, optionally under conditions suitable for expression of the trivalent bispecific antibody; and b) recovering the trivalent bispecific antibody from the cells or culture medium Including, The deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into the genome of a mammalian cell and is arranged in a 5' to 3' direction to contain: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second heavy chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, and a seventh expression cassette encoding the first light chain Contains any of the following.
[0029] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0030] One embodiment of the present invention is a 5' to 3' direction comprising: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second heavy chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, and a seventh expression cassette encoding the first light chain a deoxyribonucleic acid encoding a trivalent bispecific antibody comprising any one of:
[0031] One embodiment of the present invention is a 5' to 3' direction comprising: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second heavy chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, and a seventh expression cassette encoding the first light chain and (c) use of a deoxyribonucleic acid comprising any one of the following for expressing a trivalent bispecific antibody in a mammalian cell.
[0032] In one embodiment of the use, the deoxyribonucleic acid is integrated into the genome of the mammalian cell.
[0033] In one embodiment of the use, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0034] One aspect of the present invention is a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent bispecific antibody integrated into the genome of the cell, a deoxyribonucleic acid encoding a trivalent bispecific antibody, (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second heavy chain, a seventh expression cassette encoding a second light chain, and an eighth expression cassette encoding a second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, and a seventh expression cassette encoding the first light chain Contains any of the following.
[0035] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0036] In one embodiment of all the foregoing aspects, the deoxyribonucleic acid encoding the trivalent bispecific antibody comprises - a first recombination recognition sequence located 5' to the first (5'-most) expression cassette, - a second recombination recognition sequence located 3' to the seventh or eighth (3'-most) sequence, and between the first recombination recognition sequence and the second recombination recognition sequence, and Between two of the expression cassettes The third recombination recognition sequence located at further comprising and The recombination recognition sequences are all different.
[0037] In one embodiment, the third recombination recognition sequence is located between the fourth and fifth expression cassettes.
[0038] In one embodiment, the deoxyribonucleic acid encoding the trivalent bispecific antibody comprises a further expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal, wherein the start codon is operably linked to the coding sequence.
[0039] One embodiment of the present invention is a composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and seven expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding a second light chain, an eighth expression cassette encoding a second light chain, and - a second recombination recognition sequence or (2) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second heavy chain, a seventh expression cassette encoding a second light chain, an eighth expression cassette encoding a second light chain, and - a second recombination recognition sequence or (3) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, and - a second recombination recognition sequence Contains any of the following.
[0040] In one embodiment of all the foregoing aspects, the deoxyribonucleic acid encoding the trivalent bispecific antibody further comprises another expression cassette encoding a selectable marker.
[0041] In one embodiment, the expression cassette encoding the selectable marker comprises a third recombination recognition sequence: i) 5', or ii) 3', or iii) Partially 5' and partially 3' It is located in one of the
[0042] In one embodiment, an expression cassette encoding a selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5' portion of the expression cassette comprising a promoter and a start codon, and the 3' portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal.
[0043] In one embodiment, the portion located 5' of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent to the fourth expression cassette upstream (i.e., located downstream relative to the fourth expression cassette) and the start codon is adjacent to the third recombination recognition sequence downstream (i.e., located upstream relative to the third recombination recognition sequence); and the portion located 3' of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon, and is adjacent to the third recombination recognition sequence upstream and adjacent to the fifth expression cassette downstream.
[0044] In one embodiment, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0045] One aspect of the present invention is a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent bispecific antibody integrated into the genome of the cell, The deoxyribonucleic acid encoding the trivalent bispecific antibody comprises the following elements: first, second and third recombination recognition sequences; a first selectable marker and a second selectable marker, and 1st to 8th expression cassettes, and the sequence of the element comprises, in the 5' to 3' direction: RRS1 - 1st EC - 2nd EC - 3rd EC - 4th EC - RRS3 - SM1 - 5th EC - 6th EC - 7th EC - 8th EC - RRS2 or RRS1 - 1st EC - 2nd EC - 3rd EC - 4th EC - RRS3 - SM1 - 5th EC - 6th EC - 7th EC - RRS2 and RRS = recombination recognition sequence; EC = expression cassette; SM = selectable marker.
[0046] One embodiment of the present invention is a method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent bispecific antibody and secretes the trivalent bispecific antibody, comprising: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and wherein the recombination recognition sequences are all different; b) introducing into the cells provided in a) two deoxyribonucleic acid compositions comprising three different recombination recognition sequences and seven or eight expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding a second light chain, an eighth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second heavy chain, a seventh expression cassette encoding a second light chain, an eighth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (3) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, and - a second recombination recognition sequence including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of the second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing one or more recombinases that recognize recombination recognition sequences in the first deoxyribonucleic acid and the second deoxyribonucleic acid (and optionally the one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express a second selection marker and secrete the trivalent bispecific antibody; This results in a method for producing recombinant mammalian cells that contain deoxyribonucleic acid encoding the trivalent bispecific antibody and that secrete the trivalent bispecific antibody.
[0047] In a preferred embodiment of all aspects and embodiments, the first binding site specifically binds to the human transferrin receptor.
[0048] In one embodiment of all aspects and embodiments, the trivalent bispecific antibody is an anti-TfR / CD20 bispecific antibody. Such antibodies are reported in WO 2017 / 055542, which is incorporated herein by reference in its entirety.
[0049] In one embodiment of all aspects and embodiments, the trivalent bispecific antibody is an anti-TfR / Aβ bispecific antibody. Such antibodies are reported in WO 2017 / 055540, which is incorporated herein by reference in its entirety.
[0050] Bispecific trivalent antibodies: Described herein are recombinant mammalian cells that express trivalent antibodies, particularly bispecific trivalent antibodies such as T cell bispecific antibodies (TCBs). Trivalent antibodies are heteromultimeric polypeptides that are not naturally expressed by the mammalian cells. More specifically, trivalent antibodies are heteromultimeric proteins consisting of four polypeptides or polypeptide chains: one light chain that is a full-length light chain, an additional light chain that is a domain-swapped light chain, one heavy chain that is a full-length heavy chain, and an additional heavy chain that is an extended heavy chain containing an additional domain-swapped heavy chain or light chain Fab fragment. To achieve expression of the trivalent antibody, recombinant nucleic acids containing multiple different expression cassettes in specific and predetermined sequences are integrated into the genome of the mammalian cells.
[0051] In particular, the method according to the invention can be used to generate T cell bispecific antibodies (TCBs). These may have a format such as that described in WO 2013 / 026831. These molecules can simultaneously bind to CD3 on T cells (first specificity) and to an antigen on a target (e.g., tumor) cell (second specificity), thereby inducing target cell killing.
[0052] Also reported herein are methods for producing recombinant mammalian cells expressing trivalent antibodies, particularly trivalent bispecific antibodies, more particularly TCB, and methods for producing trivalent antibodies, particularly trivalent bispecific antibodies, more particularly TCB, using said recombinant mammalian cells.
[0053] In a preferred embodiment, the trivalent bispecific antibody comprises: a) a first Fab fragment and a second Fab fragment, each of which specifically binds to a first antigen; b) one domain-swapped Fab fragment that specifically binds to a second antigen and in which the CH1 and CL domains are replaced by each other; c) an Fc region comprising a first heavy chain Fc region polypeptide and a second heavy chain Fc region polypeptide; Including, the C-terminus of the CH1 domain of the first Fab fragment is connected to the N-terminus of one of the heavy chain Fc region polypeptides, and the C-terminus of the CL domain of the domain-exchanged Fab fragment is connected to the N-terminus of the other heavy chain Fc region polypeptide; and the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or the N-terminus of the VH domain of a domain-swapped Fab fragment; The first antigen or the second antigen is human CD3.
[0054] In a preferred embodiment, the trivalent bispecific antibody comprises: a) a first Fab fragment and a second Fab fragment, each of which specifically binds to a first antigen; b) one domain-swapped Fab fragment that specifically binds to a second antigen and in which the VH and VL domains are replaced by each other; c) an Fc region comprising a first heavy chain Fc region polypeptide and a second heavy chain Fc region polypeptide; Including, the C-terminus of the CH1 domain of the first Fab fragment is connected to the N-terminus of one of the heavy chain Fc region polypeptides, and the C-terminus of the CH1 domain of the domain-exchanged Fab fragment is connected to the N-terminus of the other heavy chain Fc region polypeptide; and the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or the N-terminus of the VL domain of the domain-swapped Fab fragment; The first antigen or the second antigen is human CD3.
[0055] In a preferred embodiment, neither the first nor the second light chain of the trivalent bispecific antibody is a common or universal light chain.
[0056] The present invention is based, at least in part, on the discovery that the sequence of different expression cassettes required for expression of heteromultimeric trivalent antibodies, i.e., expression cassette configuration, affects the expression yield of trivalent antibodies (e.g., TCB) when integrated into the genome of mammalian cells.
[0057] The present invention is based, at least in part, on the discovery that efficient recombinant expression and production of a trivalent antibody (e.g., TCB) can be achieved by integrating nucleic acids encoding a heteromultimeric trivalent antibody (e.g., TCB) having a particular expression cassette configuration into the genome of a mammalian cell.
[0058] It has been found that a given expression cassette sequence can be advantageously integrated into the genome of a mammalian cell by a dual recombinase-mediated cassette exchange reaction.
[0059] One embodiment according to the present invention is a method for producing a trivalent antibody (e.g., a TCB), comprising: a) optionally culturing mammalian cells comprising deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB) under conditions suitable for expression of the trivalent antibody (e.g., TCB); and b) recovering the trivalent antibody (e.g., TCB) from the cells or culture medium Including, The deoxyribonucleic acid encoding the trivalent antibody (e.g., TCB) is stably integrated into the genome of a mammalian cell and is arranged in the 5' to 3' direction as follows: One of the following: 1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and optionally a sixth expression cassette encoding a second light chain, or 2) a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain, The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in the same direction and in the opposite direction to the first to third expression cassettes, or or 3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a first light chain, or a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain Includes:
[0060] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (numbering according to Kabat). In one embodiment, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment. In one embodiment, the first light chain is a domain-swapped light chain.
[0061] In one embodiment, the deoxyribonucleic acid comprises a further expression cassette between the first and second expression cassettes encoding a second heavy chain.
[0062] In one embodiment, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0063] In one embodiment, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0064] In one embodiment, the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0065] One embodiment of the present invention is a 5' to 3' direction comprising: One of the following: 1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and optionally a sixth expression cassette encoding a second light chain, or 2) a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain, The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in the same direction and in the opposite direction to the first to third expression cassettes, or or 3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a first light chain, or a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain and a deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB) comprising:
[0066] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (numbering according to Kabat). In one embodiment, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment. In one embodiment, the first light chain is a domain-swapped light chain.
[0067] In one embodiment, the deoxyribonucleic acid comprises a further expression cassette between the first and second expression cassettes encoding a second heavy chain.
[0068] In one embodiment, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0069] In one embodiment, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0070] One embodiment of the present invention is a 5' to 3' direction comprising: One of the following: 1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and optionally a sixth expression cassette encoding a second light chain, or 2) a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain, The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in the same direction and in the opposite direction to the first to third expression cassettes, or or 3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a first light chain, or a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain and the use of a deoxyribonucleic acid comprising the following for expressing a trivalent antibody (e.g., TCB) in mammalian cells.
[0071] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (numbering according to Kabat). In one embodiment, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment. In one embodiment, the first light chain is a domain-swapped light chain.
[0072] In one embodiment, the deoxyribonucleic acid comprises a further expression cassette between the first and second expression cassettes encoding a second heavy chain.
[0073] In one embodiment, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0074] In one embodiment, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0075] In one embodiment of the use, the deoxyribonucleic acid is integrated into the genome of the mammalian cell.
[0076] In one embodiment of the use, the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0077] One aspect of the present invention is a recombinant mammalian cell comprising, integrated into the genome of the cell, a deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB), The deoxyribonucleic acid encoding the trivalent antibody (e.g., TCB) comprises, in the 5' to 3' direction: One of the following: 1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and optionally a sixth expression cassette encoding a second light chain, or 2) a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and - a sixth expression cassette encoding a second light chain, The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in the same direction and in the opposite direction to the first to third expression cassettes, or or 3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a first light chain, or a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain Includes:
[0078] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (numbering according to Kabat). In one embodiment, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment. In one embodiment, the first light chain is a domain-swapped light chain.
[0079] In one embodiment, the deoxyribonucleic acid comprises a further expression cassette between the first and second expression cassettes encoding a second heavy chain.
[0080] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0081] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0082] In one embodiment, the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0083] In one embodiment of all the foregoing aspects and embodiments, the deoxyribonucleic acid encoding the trivalent antibody (e.g., TCB) comprises: - a first recombination recognition sequence located 5' to the first (5'-most) expression cassette, a second recombination recognition sequence located 3' to the sixth (3'-most) expression cassette, and between the first recombination recognition sequence and the second recombination recognition sequence, and Between two of the expression cassettes and further comprising a third recombination recognition sequence located at and The recombination recognition sequences are all different.
[0084] In one embodiment of all the foregoing aspects and embodiments, the third recombination recognition sequence is located between the third expression cassette and the fourth expression cassette.
[0085] In one embodiment of all the foregoing aspects and embodiments, the deoxyribonucleic acid encoding the trivalent antibody (e.g., TCB) comprises a further expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, wherein the 5'-located portion of the expression cassette comprises a promoter and a start codon, and the 3'-located portion of the expression cassette comprises a coding sequence without a start codon and a polyA signal, wherein the start codon is operably linked to the coding sequence.
[0086] One embodiment of the present invention is a composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and six expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, - a first copy of a third recombination recognition sequence Including, and a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding a second light chain, and - a second recombination recognition sequence Includes:
[0087] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (numbering according to Kabat). In one embodiment, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment. In one embodiment, the first light chain is a domain-swapped light chain.
[0088] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0089] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0090] In one embodiment of all the foregoing aspects and embodiments, the deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) further comprises another expression cassette encoding a selectable marker.
[0091] In one embodiment of all the foregoing aspects and embodiments, the expression cassette encoding the selectable marker comprises a third recombination recognition sequence: i) 5', or ii) 3', or iii) Partially 5' and partially 3' It is located in one of the
[0092] In one embodiment of all the foregoing aspects and embodiments, an expression cassette encoding a selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal.
[0093] In one embodiment of all the foregoing aspects and embodiments, the portion located 5' of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent to a third expression cassette upstream (i.e., located downstream relative to the third expression cassette) and the start codon is adjacent to a third recombination recognition sequence downstream (i.e., located upstream relative to the third recombination recognition sequence), and the portion located 3' of the expression cassette encoding the selectable marker comprises nucleic acid encoding a selectable marker lacking a start codon and is adjacent to the third recombination recognition sequence upstream and adjacent to a fourth expression cassette downstream.
[0094] In one embodiment of all the foregoing aspects and embodiments, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0095] One aspect of the present invention is a recombinant mammalian cell comprising, integrated into the genome of the cell, a deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB), A deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB) may contain the following elements: first, second and third recombination recognition sequences; a first selectable marker and a second selectable marker, and First to sixth expression cassettes, and in the 5' to 3' direction, the sequence of the element comprises: RRS1 - 1st EC - 2nd EC - 3rd EC - RRS3 - SM1 - 4th EC - 5th EC - 6th EC - RRS2 and RRS = recombination recognition sequence; EC = expression cassette; SM = selectable marker.
[0096] One embodiment of the present invention is a method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB) and secretes the trivalent antibody (e.g., TCB), comprising: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and wherein the recombination recognition sequences are all different; b) introducing into the cells provided in a) a composition comprising two deoxyribonucleic acids comprising three different recombination recognition sequences and six expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction: -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, - a 5'-end portion of an expression cassette encoding a second selection marker, and - a first copy of a third recombination recognition sequence Including, and a second deoxyribonucleic acid in the 5' to 3' direction: - a second copy of a third recombination recognition sequence, - the 3'-end portion of an expression cassette encoding a second selection marker, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding a second light chain, and - a second recombination recognition sequence wherein the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the exogenous nucleotide sequence to be integrated; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of the second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing one or more recombinases that recognize and introduce recombination recognition sequences in the first and second deoxyribonucleic acids (and optionally, the one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express a second selection marker and secrete a trivalent antibody (e.g., TCB); This results in a method for producing recombinant mammalian cells that contain deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) and that secrete the trivalent antibody (eg, TCB).
[0097] In a preferred embodiment of all the above aspects and embodiments, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (numbering according to Kabat). In one embodiment, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment.
[0098] In one embodiment of all the foregoing aspects and embodiments, the first light chain is a domain-swapped light chain.
[0099] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0100] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0101] In one embodiment of all the above aspects and embodiments, an expression cassette encoding one second selection marker is located partially 5' and partially 3' of the third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising the coding sequence of one second selection marker without a start codon and a polyA signal.
[0102] In one embodiment of all the foregoing aspects and embodiments, the 5'-end portion of the expression cassette encoding one second selection marker comprises a promoter sequence operably linked to a start codon, the promoter sequence being adjacent to the expression cassette upstream (i.e., located downstream relative to the expression cassette), and the start codon being adjacent to a third recombination recognition sequence downstream (i.e., located upstream relative to the third recombination recognition sequence); and the 3'-end portion of the expression cassette encoding one second selection marker comprises a coding sequence for one second selection marker lacking a start codon, being adjacent to the third recombination recognition sequence upstream and adjacent to the expression cassette downstream.
[0103] In one embodiment of all the foregoing aspects and embodiments, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0104] In one embodiment of all the foregoing aspects and embodiments, i) a first expression cassette comprising, in the 5' to 3' direction, a promoter, a nucleic acid encoding a first heavy chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; ii) the second expression cassette comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the first light chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; iii) a third expression cassette comprising, in the 5' to 3' direction, a promoter, a nucleic acid encoding the first light chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; iv) a fourth expression cassette comprising, in the 5' to 3' direction, a promoter, a nucleic acid encoding a second heavy chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; v) a fifth expression cassette comprising, in the 5' to 3' direction, a promoter, a nucleic acid encoding a second light chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; vi) a sixth expression cassette comprising, in the 5' to 3' direction, a promoter, a nucleic acid encoding a second light chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; and (vii) The expression cassette encoding the selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the selectable marker, and a polyadenylation signal sequence, and optionally, a terminator sequence.
[0105] In one embodiment of all aspects and embodiments, the trivalent bispecific antibody (TCB) comprises: a first Fab fragment and a second Fab fragment, wherein each binding site of the first Fab fragment and the second Fab fragment specifically binds to a second antigen; a third Fab fragment, wherein the binding site of the third Fab fragment specifically binds to the first antigen and comprises a domain crossover such that the variable light domain (VL) and the variable heavy domain (VH) are interchanged; and an Fc region comprising a first Fc region polypeptide and a second Fc region polypeptide; Including, the first Fab fragment and the second Fab fragment each comprise a heavy chain fragment and a full-length light chain; the C-terminus of the heavy chain fragment of the first Fab fragment is fused to the N-terminus of the first Fc region polypeptide; The C-terminus of the heavy chain fragment of the second Fab fragment is fused to the N-terminus of the variable light chain domain of the third Fab fragment, and the C-terminus of heavy chain constant domain 1 of the third Fab fragment is fused to the N-terminus of the second Fc region polypeptide.
[0106] In one embodiment of all aspects and embodiments herein, the at least one selectable marker expression cassette is oriented in the opposite direction to the antibody heavy and light chain expression cassettes.
[0107] In one embodiment of all aspects and embodiments herein, the antibody heavy chain expression cassette and the antibody light chain expression cassette are unidirectionally arranged relative to each other (i.e., having the same orientation from 3' to 5'), and at least one of the selectable marker expression cassettes is bidirectionally arranged relative to the antibody heavy chain expression cassette and the antibody light chain expression cassette.
[0108] In one embodiment of all aspects and embodiments, the trivalent antibody is an anti-CD3 / CD20 bispecific antibody. In one embodiment, the anti-CD3 / CD20 bispecific antibody is TCB, and CD20 is the second antigen. In one embodiment, the bispecific anti-CD3 / CD20 antibody is RG6026. Such antibodies are reported in WO 2016 / 020309, the entire contents of which are incorporated herein by reference.
[0109] In one embodiment of all aspects and embodiments, the trivalent antibody is an anti-CD3 / CEA bispecific antibody. In one embodiment, the anti-CD3 / CEA bispecific antibody is TCB, and CEA is the second antigen. In one embodiment, the bispecific anti-CD3 / CEA antibody is RO6958688, RG7802, or civisatamab. Such antibodies are reported in WO 2017 / 055389, the entire contents of which are incorporated herein by reference.
[0110] In a preferred embodiment of all aspects and embodiments, the first binding site specifically binds to human CD3.
[0111] In a preferred embodiment of all aspects and embodiments, the second binding site specifically binds to human CD3.
[0112] Bivalent bispecific antibodies with domain swapping: This specification reports recombinant mammalian cells that express bivalent bispecific antibodies, particularly bivalent bispecific antibodies with domain swapping. Bivalent bispecific antibodies are heteromultimeric polypeptides that are not naturally expressed by the mammalian cells. More specifically, bivalent bispecific antibodies are heteromultimeric proteins consisting of four polypeptides or polypeptide chains: one light chain that is a full-length light chain, an additional light chain that is a domain-swapped light chain, one heavy chain that is a full-length heavy chain, and an additional heavy chain that is a domain-swapped heavy chain. To achieve expression of bivalent bispecific antibodies, recombinant nucleic acids containing multiple different expression cassettes in specific and predetermined sequences are integrated into the genome of mammalian cells.
[0113] Also reported herein are methods for making recombinant mammalian cells that express bivalent, bispecific antibodies and methods for producing bivalent, bispecific antibodies using said recombinant mammalian cells.
[0114] In a preferred embodiment, the bivalent, bispecific antibody comprises: a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; a second heavy chain comprising, from N-terminus to C-terminus, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; - a first light chain comprising, from the N-terminus to the C-terminus, a second heavy chain variable domain and a CL domain; and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain Including, The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0115] In a preferred embodiment, the bivalent, bispecific antibody comprises: a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; a second heavy chain comprising, from N-terminus to C-terminus, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain; a first light chain comprising, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain Including, The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0116] The present invention is based, at least in part, on the discovery that the sequences of different expression cassettes required for expression of heteromultimeric bivalent bispecific antibodies, i.e., expression cassette configuration, affect the expression yield of the bivalent bispecific antibody when integrated into the genome of a mammalian cell.
[0117] The present invention is based, at least in part, on the discovery that efficient recombinant expression and production of bivalent bispecific antibodies can be achieved by integrating nucleic acids encoding heteromultimeric bivalent bispecific antibodies with specific expression cassette configurations into the genome of mammalian cells.
[0118] It has been found that a given expression cassette sequence can be advantageously integrated into the genome of a mammalian cell by a dual recombinase-mediated cassette exchange reaction.
[0119] One embodiment according to the present invention is a method for producing a bivalent, bispecific antibody, comprising: a) culturing mammalian cells comprising deoxyribonucleic acid encoding the bivalent, bispecific antibody, optionally under conditions suitable for expression of the bivalent, bispecific antibody; and b) recovering the bivalent, bispecific antibody from the cells or culture medium Including, The deoxyribonucleic acid encoding the bivalent, bispecific antibody is stably integrated into the genome of a mammalian cell and is arranged in the 5' to 3' direction as follows: (1) a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain, or (2) a first expression cassette encoding a first light chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding the first heavy chain Includes:
[0120] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0121] One embodiment of the present invention is a 5' to 3' direction comprising: (1) a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain, or (2) a first expression cassette encoding a first light chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding the first heavy chain a deoxyribonucleic acid encoding a bivalent, bispecific antibody comprising any one of:
[0122] One embodiment of the present invention is a 5' to 3' direction comprising: (1) a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain, or (2) a first expression cassette encoding a first light chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding the first heavy chain and (c) use of a deoxyribonucleic acid comprising any one of the following for expressing a bivalent, bispecific antibody in a mammalian cell.
[0123] In one embodiment of the use, the deoxyribonucleic acid is integrated into the genome of the mammalian cell.
[0124] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0125] One aspect of the present invention is a recombinant mammalian cell comprising, integrated into the genome of the cell, a deoxyribonucleic acid encoding a bivalent, bispecific antibody, The deoxyribonucleic acid encoding the bivalent, bispecific antibody comprises, in the 5' to 3' direction: (1) a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain, or (2) a first expression cassette encoding a first light chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding the first heavy chain a deoxyribonucleic acid encoding a bivalent, bispecific antibody comprising any one of:
[0126] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0127] In one embodiment of all the foregoing aspects, the deoxyribonucleic acid encoding the bivalent, bispecific antibody comprises - a first recombination recognition sequence located 5' to the first (5'-most) expression cassette, a second recombination recognition sequence located 3' to the fourth (3'-most) expression cassette, and between the first recombination recognition sequence and the second recombination recognition sequence, and Between two of the expression cassettes The third recombination recognition sequence located at further comprising and The recombination recognition sequences are all different.
[0128] In one embodiment, the third recombination recognition sequence is located between the second expression cassette and the third expression cassette.
[0129] In one embodiment, the deoxyribonucleic acid encoding the bivalent, bispecific antibody comprises a further expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal, wherein the start codon is operably linked to the coding sequence.
[0130] One embodiment of the present invention is a composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and eight expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) -first recombination recognition sequence a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence, or (2) -first recombination recognition sequence a first expression cassette encoding a first light chain, a second expression cassette encoding a second heavy chain, and - a first copy of a third recombination recognition sequence including any of the following: and a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a third expression cassette encoding a second light chain, a fourth expression cassette encoding the first heavy chain, and - a second recombination recognition sequence Contains any of the following.
[0131] In one embodiment, the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (1), or the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (2).
[0132] In one embodiment of all the foregoing aspects, the deoxyribonucleic acid encoding the bivalent, bispecific antibody further comprises another expression cassette encoding a selectable marker.
[0133] In one embodiment, the expression cassette encoding the selectable marker comprises a third recombination recognition sequence: i) 5', or ii) 3', or iii) Partially 5' and partially 3' It is located in one of the
[0134] In one embodiment, an expression cassette encoding a selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5' portion of the expression cassette comprising a promoter and a start codon, and the 3' portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal.
[0135] In one embodiment, the 5'-located portion of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent to the second expression cassette upstream (i.e., located downstream relative to the second expression cassette) and the start codon is adjacent to the third recombination recognition sequence downstream (i.e., located upstream relative to the third recombination recognition sequence), and the 3'-located portion of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon and is adjacent to the third recombination recognition sequence upstream and adjacent to the third expression cassette downstream.
[0136] In one embodiment, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0137] One aspect of the present invention is a recombinant mammalian cell comprising, integrated into the genome of the cell, a deoxyribonucleic acid encoding a bivalent, bispecific antibody, The deoxyribonucleic acid encoding the bivalent, bispecific antibody comprises the following elements: first, second and third recombination recognition sequences; a first selectable marker and a second selectable marker, and Expression cassettes 1 to 4 and in the 5' to 3' direction, the sequence of the element comprises: RRS1 - 1st EC - 2nd EC - RRS3 - SM1 - 3rd EC - 4th EC - RRS2 and RRS = recombination recognition sequence; EC = expression cassette; SM = selectable marker.
[0138] One embodiment of the present invention is a method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a bivalent, bispecific antibody and secretes the bivalent, bispecific antibody, comprising: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and wherein the recombination recognition sequences are all different; b) introducing into the cells provided in a) a composition comprising two deoxyribonucleic acids comprising three different recombination recognition sequences and four expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) -first recombination recognition sequence a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence or (2) -first recombination recognition sequence a first expression cassette encoding a first light chain, a second expression cassette encoding a second heavy chain, and - a first copy of a third recombination recognition sequence including any of the following: and a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, and - a second recombination recognition sequence or (2) - a second copy of a third recombination recognition sequence, a third expression cassette encoding a second light chain, a fourth expression cassette encoding the first heavy chain, and - a second recombination recognition sequence including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the exogenous nucleotide sequence to be integrated; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of the second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing one or more recombinases that recognize and introduce recombination recognition sequences in the first and second deoxyribonucleic acids (and optionally, the one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express a second selectable marker and secrete a bivalent, bispecific antibody; This results in a method for producing recombinant mammalian cells that contain deoxyribonucleic acid encoding the bivalent, bispecific antibody and that secrete the bivalent, bispecific antibody.
[0139] In one embodiment, the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (1), or the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (2).
[0140] In one embodiment of all aspects and embodiments, the bivalent, bispecific antibody is an anti-ANG2 / VEGF bispecific antibody. In one embodiment, the bispecific anti-ANG2 / VEGF antibody is RG7221 or vanucizumab.
[0141] In one embodiment of all aspects and embodiments, the bivalent, bispecific antibody is an anti-ANG2 / VEGF bispecific antibody. In one embodiment, the bispecific anti-ANG2 / VEGF antibody is RG7716 or faricimab.
[0142] Such ANG2 / VEGF bispecific antibodies are reported in WO 2010 / 040508, WO 2011 / 117329, WO 2014 / 009465, which are incorporated herein by reference in their entireties.
[0143] In one embodiment of all aspects and embodiments, the bivalent, bispecific antibody is an anti-PD1 / TIM3 bispecific antibody. Such antibodies are reported in WO 2017 / 055404, which is incorporated herein by reference in its entirety.
[0144] In one embodiment of all aspects and embodiments, the bivalent, bispecific antibody is an anti-PD1 / Lag3 bispecific antibody. Such antibodies are reported in WO 2018 / 185043, which is incorporated herein by reference in its entirety.
[0145] Multivalent bispecific antibodies: Recombinant mammalian cells expressing multivalent bispecific antibodies are reported herein. Multivalent bispecific antibodies are heteromultimeric polypeptides not naturally expressed by the mammalian cells. More specifically, multivalent bispecific antibodies are heteromultimeric proteins consisting of three polypeptides or polypeptide chains: one light chain that is a full-length light chain; one heavy chain that is an extended heavy chain containing an additional N-terminal heavy chain Fab fragment and an additional C-terminal light chain variable domain; and an additional heavy chain that is an extended heavy chain containing an additional N-terminal heavy chain Fab fragment and an additional C-terminal heavy chain variable domain. To achieve expression of multivalent bispecific antibodies, recombinant nucleic acids containing multiple different expression cassettes in specific and predetermined sequences are integrated into the genome of mammalian cells. In a preferred embodiment, the multivalent bispecific antibody is at least tetravalent. In a preferred embodiment, the multivalent bispecific antibody is at most 10-valent, more preferably at most octavalent.
[0146] Also reported herein are methods for making recombinant mammalian cells that express multivalent, bispecific antibodies and methods for producing multivalent, bispecific antibodies using said recombinant mammalian cells.
[0147] In a preferred embodiment, the multivalent, bispecific antibody comprises: a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second copy of the first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a first light chain variable domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second copy of the first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a second heavy chain variable domain; and a first light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain Including, The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0148] In a preferred embodiment, neither the first nor the second light chain of the multivalent bispecific antibody is a common or universal light chain.
[0149] The present invention is based, at least in part, on the discovery that the sequences of different expression cassettes required for expression of heteromultimeric multivalent bispecific antibodies, i.e., the expression cassette configuration, influence the expression yield of the multivalent bispecific antibody when integrated into the genome of a mammalian cell.
[0150] The present invention is based, at least in part, on the discovery that efficient recombinant expression and production of multivalent bispecific antibodies can be achieved by integrating nucleic acids encoding heteromultimeric multivalent bispecific antibodies with specific expression cassette configurations into the genome of mammalian cells.
[0151] It has been found that a given expression cassette sequence can be advantageously integrated into the genome of a mammalian cell by a dual recombinase-mediated cassette exchange reaction.
[0152] One embodiment according to the present invention is a method for producing a multivalent, bispecific antibody, comprising: a) optionally culturing mammalian cells comprising deoxyribonucleic acid encoding the multivalent, bispecific antibody under conditions suitable for expression of the multivalent, bispecific antibody; and b) recovering the multivalent, bispecific antibody from the cells or culture medium Including, The deoxyribonucleic acid encoding the multivalent, bispecific antibody is stably integrated into the genome of a mammalian cell and is arranged in a 5' to 3' direction as follows: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a first light chain, and a sixth expression cassette encoding a first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain Contains any of the following.
[0153] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0154] One embodiment of the present invention is a 5' to 3' direction comprising: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a first light chain, and a sixth expression cassette encoding a first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain a deoxyribonucleic acid encoding a multivalent, bispecific antibody comprising any one of:
[0155] One embodiment of the present invention is a 5' to 3' direction comprising: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a first light chain, and a sixth expression cassette encoding a first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain and (c) use of a deoxyribonucleic acid comprising any one of the following for expressing a multivalent, bispecific antibody in a mammalian cell.
[0156] In one embodiment of the use, the deoxyribonucleic acid is integrated into the genome of the mammalian cell.
[0157] In one embodiment of the use, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0158] One aspect of the present invention is a recombinant mammalian cell comprising, integrated into the genome of the cell, a deoxyribonucleic acid encoding a multivalent, bispecific antibody, The deoxyribonucleic acid encoding the multivalent, bispecific antibody comprises, in the 5' to 3' direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a first light chain, and a sixth expression cassette encoding a first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain a deoxyribonucleic acid encoding a multivalent, bispecific antibody comprising any one of:
[0159] In one embodiment, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0160] In one embodiment of all the foregoing aspects, the deoxyribonucleic acid encoding the multivalent, bispecific antibody comprises: - a first recombination recognition sequence located 5' to the first (5'-most) expression cassette, a second recombination recognition sequence located 3' to the sixth or eighth (3'-most) expression cassette, and between the first recombination recognition sequence and the second recombination recognition sequence, and Between two of the expression cassettes The third recombination recognition sequence located at further comprising and All recombination recognition sequences are different.
[0161] In one embodiment, the third recombination recognition sequence is located between the third and fourth expression cassettes, or between the fourth and fifth expression cassettes.
[0162] In one embodiment, the deoxyribonucleic acid encoding the multivalent, bispecific antibody comprises a further expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker being partially located 5' and partially located 3' of a third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal, the start codon being operably linked to the coding sequence.
[0163] One embodiment of the present invention is a composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and eight expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, - a first copy of a third recombination recognition sequence or (2) -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, and - a first copy of a third recombination recognition sequence including any of the following: and a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a first light chain, and a sixth expression cassette encoding a first light chain, and - a second recombination recognition sequence or (2) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, an eighth expression cassette encoding a first light chain, and - a second recombination recognition sequence Contains any of the following.
[0164] In one embodiment, the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (1), or the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (2).
[0165] In one embodiment of all the foregoing aspects, the deoxyribonucleic acid encoding the multivalent, bispecific antibody further comprises another expression cassette encoding a selectable marker.
[0166] In one embodiment, the expression cassette encoding the selectable marker comprises a third recombination recognition sequence: i) 5', or ii) 3', or iii) Partially 5' and partially 3'
[0167] It is located in one of the
[0168] In one embodiment, an expression cassette encoding a selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5' portion of the expression cassette comprising a promoter and a start codon, and the 3' portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal.
[0169] In one embodiment, the 5'-located portion of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent upstream to the third or fourth expression cassette, respectively (i.e., located downstream relative to the third or fourth expression cassette), and the start codon is adjacent downstream to the third recombination recognition sequence (i.e., located upstream relative to the third recombination recognition sequence), and the 3'-located portion of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon and is adjacent upstream to the third recombination recognition sequence and downstream to the fourth or fifth expression cassette, respectively.
[0170] In one embodiment, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0171] One aspect of the present invention is a recombinant mammalian cell comprising, integrated into the genome of the cell, a deoxyribonucleic acid encoding a multivalent, bispecific antibody, The deoxyribonucleic acid encoding the multivalent, bispecific antibody comprises the following elements: first, second and third recombination recognition sequences; a first selectable marker and a second selectable marker, and 1st to 6th or 1st to 8th expression cassettes and in the 5' to 3' direction, the sequence of the element comprises: RRS1 - 1st EC - 2nd EC - 3rd EC - RRS3 - SM1 - 4th EC - 5th EC - 6th EC - RRS2 or RRS1 - 1st EC - 2nd EC - 3rd EC - 4th EC - RRS3 - SM1 - 5th EC - 6th EC - 7th EC - 8th EC - RRS2 and RRS = recombination recognition sequence; EC = expression cassette; SM = selectable marker.
[0172] One embodiment of the present invention is a method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a multivalent, bispecific antibody and secretes the multivalent, bispecific antibody, comprising: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and wherein the recombination recognition sequences are all different; b) introducing into the cells provided in a) a composition comprising two deoxyribonucleic acids comprising three different recombination recognition sequences and six or eight expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, - a first copy of a third recombination recognition sequence, or (2) -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, and - a first copy of a third recombination recognition sequence including any of the following: and a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, a sixth expression cassette encoding a first light chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding the first light chain, an eighth expression cassette encoding a first light chain, and - a second recombination recognition sequence including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the exogenous nucleotide sequence to be integrated; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of the second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing one or more recombinases that recognize and introduce recombination recognition sequences in the first and second deoxyribonucleic acids (and optionally, the one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express a second selection marker and secrete multivalent bispecific antibodies; This results in a method for producing recombinant mammalian cells that contain deoxyribonucleic acid encoding the multivalent bispecific antibody and that secrete the multivalent bispecific antibody.
[0173] In one embodiment, the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (1), or the first deoxyribonucleic acid and the second deoxyribonucleic acid both comprise a configuration according to (2).
[0174] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a first light chain variable domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a second heavy chain variable domain; and the first light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0175] In one embodiment of all the foregoing aspects and embodiments, each expression cassette comprises, in 5' to 3' direction, a promoter, a coding sequence, and a polyadenylation signal sequence, optionally followed by a terminator sequence.
[0176] In one embodiment of all the foregoing aspects and embodiments, all expression cassettes are arranged in one direction.
[0177] In one embodiment of all aspects and embodiments, the multivalent bispecific antibody is an anti-FAP / Ox40 bispecific antibody. Such antibodies are reported in WO 2017 / 060144, which is incorporated herein by reference in its entirety.
[0178] Targeted integration using Cre mRNA: Also reported herein are methods for making recombinant mammalian cells that express heterologous polypeptides and methods for producing heterologous polypeptides using said recombinant mammalian cells.
[0179] The present invention is based, at least in part, on the discovery that the number of clones obtained by targeted integration can be improved by using, for example, Cre recombinase mRNA (Cre mRNA) instead of Cre recombinase DNA (Cre DNA). More specifically, it was found that after a selection period, the absolute number of clones in a Cre mRNA-generated recombinant cell pool was greater than that in a CRE plasmid-generated recombinant cell pool. Therefore, for example, by using Cre mRNA instead of a plasmid encoding Cre recombinase (Cre plasmid), a recombinant cell pool with increased clone number and heterogeneity can be obtained. Without being bound by this theory, it is assumed that this increases the probability of finding recombinant cell clones with high titers and good product quality. Furthermore, it was found that the increase in the number of recombinant cell clones from the Cre mRNA-generated pool was stable compared to the Cre plasmid-generated cell pool.
[0180] It should be pointed out that the Cre mRNA introduced for the recombinase reaction is the isolated Cre mRNA and is the only source of Cre recombinase in the method according to the invention.
[0181] An independent aspect of the present invention is a method for producing a polypeptide, comprising: a) optionally culturing mammalian cells containing deoxyribonucleic acid encoding the polypeptide under conditions suitable for expression of the polypeptide; and b) recovering the polypeptide from the cells or culture medium Including, A method in which a deoxyribonucleic acid encoding a polypeptide is stably integrated into the genome of a mammalian cell by Cre recombinase-mediated cassette exchange using Cre mRNA.
[0182] Another independent aspect of the invention is a method for producing a recombinant mammalian cell that contains a deoxyribonucleic acid encoding a polypeptide and that secretes the polypeptide, comprising: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and wherein the recombination recognition sequences are all different; b) introducing into the cells provided in a) a composition comprising two deoxyribonucleic acids comprising three different recombination recognition sequences and 1 to 8 expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction: -first recombination recognition sequence one or more expression cassettes, - a 5'-end portion of an expression cassette encoding a second selection marker, and - a first copy of a third recombination recognition sequence including any of the following: and a second deoxyribonucleic acid in the 5' to 3' direction: - a second copy of a third recombination recognition sequence, - the 3'-end portion of an expression cassette encoding a second selection marker, one or more expression cassettes, and - a second recombination recognition sequence including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the exogenous nucleotide sequence to be integrated; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of the second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially A step of introducing Cre recombinase mRNA into the vector, a Cre recombinase recognizing and introducing recombination recognition sequences of the first and second deoxyribonucleic acids (and optionally, the recombinase performs two recombinase-mediated cassette exchange); and d) selecting cells that express a second selectable marker and secrete the polypeptide; This results in the production of recombinant mammalian cells that contain deoxyribonucleic acid encoding the polypeptide and that secrete the polypeptide.
[0183] Another aspect of the invention is the use of Cre-recombinase mRNA to increase the number of recombinant mammalian cells that contain (exactly one copy of) a (heterologous and / or transgenic) deoxyribonucleic acid encoding a (heterologous) polypeptide of interest stably integrated by targeted integration into a single site in the genome of said recombinant mammalian cells, and in one embodiment the recombinant cells also secrete the polypeptide of interest into the culture medium when cultured therein.
[0184] In one embodiment of all aspects and embodiments according to the invention, the mammalian cell and / or the introduced Cre recombinase mRNA does not comprise a deoxyribonucleic acid encoding Cre recombinase.
[0185] In one embodiment of all aspects and embodiments according to the present invention, the Cre recombinase mRNA is an isolated Cre recombinase mRNA.
[0186] In one embodiment of all aspects and embodiments according to the invention, the Cre mRNA encodes a polypeptide having the amino acid sequence of SEQ ID NO:20.
[0187] In one embodiment of all aspects and embodiments according to the invention, the Cre mRNA encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 20 and further comprising a nuclear localization sequence at its N-terminus or C-terminus, or both. In one embodiment, the Cre mRNA encodes a polypeptide having the amino acid sequence of SEQ ID NO: 20 and further comprising, independently of each other, one to five nuclear localization sequences at its N-terminus or C-terminus, or both.
[0188] In one embodiment of all aspects and embodiments according to the invention, the Cre mRNA comprises the amino acid sequence of SEQ ID NO: 21 or a codon usage optimized variant thereof. In one embodiment of all aspects, the Cre mRNA comprises the nucleotide sequence of SEQ ID NO: 21 or a codon usage optimized variant thereof, and further comprises at its 5'-end or 3'-end or both, an additional nucleic acid encoding a nuclear localization sequence. In one embodiment of all aspects, the Cre mRNA comprises the nucleotide sequence of SEQ ID NO: 21 or a codon usage optimized variant thereof, and further comprises at its 5'-end or 3'-end or both, independently of each other, 1 to 5 nucleic acids encoding nuclear localization sequences.
[0189] In one embodiment of all aspects and embodiments according to the invention, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0190] In one embodiment of all aspects and embodiments according to the invention, the deoxyribonucleic acid encoding the polypeptide comprises 1 to 8 expression cassettes.
[0191] In one embodiment of all aspects and embodiments according to the invention, the deoxyribonucleic acid encoding the polypeptide comprises at least four expression cassettes, - the first recombination recognition sequence is located 5' to the 5'-most (i.e., first) expression cassette, the second recombination recognition sequence is located 3' to the 3'-most expression cassette (i.e. the last expression cassette), and the third recombination recognition sequence is between the first recombination recognition sequence and the second recombination recognition sequence, and Between two of the expression cassettes Located in and All recombination recognition sequences are different.
[0192] In one embodiment of all aspects and embodiments according to the present invention, the third recombination recognition sequence is located between the second expression cassette and the third expression cassette, or between the third expression cassette and the fourth expression cassette, or between the fourth expression cassette and the fifth expression cassette.
[0193] In one embodiment of all aspects and embodiments according to the present invention, the deoxyribonucleic acid encoding the polypeptide further comprises an expression cassette encoding a selectable marker.
[0194] In one embodiment of all aspects and embodiments according to the invention, the deoxyribonucleic acid encoding the polypeptide comprises a further expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker being located partly 5' and partly 3' to a third recombination recognition sequence, the part of said expression cassette located 5' comprises a promoter and a start codon, and the part of said expression cassette located 3' comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence.
[0195] In one embodiment of all aspects and embodiments according to the invention, the expression cassette encoding the selectable marker comprises a third recombination recognition sequence: i) 5', or ii) 3', or iii) Partially 5' and partially 3' It is located in one of the
[0196] In one embodiment of all aspects and embodiments according to the invention, the polypeptide is selected from the group of polypeptides consisting of bivalent monospecific antibodies, bivalent bispecific antibodies, bivalent bispecific antibodies comprising at least one domain swap, and trivalent bispecific antibodies comprising at least one domain swap.
[0197] In one embodiment of all aspects and embodiments according to the present invention, the polypeptide is a heterotetrameric polypeptide, a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; a first light chain comprising, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain; is a polypeptide comprising The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0198] In one embodiment of all aspects and embodiments according to the present invention, the polypeptide is a heterotetrameric polypeptide, a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain, and a CH3 domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; a first light chain comprising, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain; is a polypeptide comprising The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0199] In one embodiment of all aspects and embodiments according to the present invention, the polypeptide is a heterotetrameric polypeptide, a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; a second heavy chain comprising, from N-terminus to C-terminus, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, a first light chain comprising, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain; is a polypeptide comprising The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0200] In one embodiment of all aspects and embodiments according to the present invention, the polypeptide is a heterotetrameric polypeptide, a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain, a first light chain comprising, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain; is a polypeptide comprising The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0201] In one embodiment of all aspects and embodiments according to the present invention, the polypeptide is a heteromultimeric polypeptide, a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a first light chain variable domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a second heavy chain variable domain; and a first light chain comprising, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; is a polypeptide comprising The first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0202] In one embodiment of all aspects and embodiments according to the present invention, the polypeptide is a heterotetrameric polypeptide, a first heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; a second heavy chain comprising, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain; a first light chain comprising, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and a second light chain comprising, from the N-terminus to the C-terminus, a second light chain variable domain and a CL domain; is a polypeptide comprising The second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site.
[0203] In one embodiment of all aspects and embodiments according to the invention, the polypeptide is a therapeutic antibody. In a preferred embodiment, the therapeutic antibody is a bispecific (therapeutic) antibody. In one embodiment, the bispecific (therapeutic) antibody is TCB.
[0204] In one embodiment of all aspects and embodiments, the polypeptide is a bispecific (therapeutic) antibody (TCB), a first Fab fragment and a second Fab fragment, wherein each binding site of the first Fab fragment and the second Fab fragment specifically binds to a second antigen; a third Fab fragment, wherein the binding site of the third Fab fragment specifically binds to the first antigen and comprises a domain crossover such that the variable light domain (VL) and the variable heavy domain (VH) are substituted for each other; an Fc region comprising a first Fc region polypeptide and a second Fc region polypeptide; Including, the first Fab fragment and the second Fab fragment each comprise a heavy chain fragment and a full-length light chain; the C-terminus of the heavy chain fragment of the first Fab fragment is fused to the N-terminus of the first Fc region polypeptide; A bispecific (therapeutic) antibody (TCB) in which the C-terminus of the heavy chain fragment of a second Fab fragment is fused to the N-terminus of the variable light chain domain of a third Fab fragment, and the C-terminus of heavy chain constant domain 1 of the third Fab fragment is fused to the N-terminus of a second Fc region polypeptide.
[0205] In one embodiment of all aspects and embodiments according to the invention, the polypeptide is an anti-CD3 / CD20 bispecific antibody. In one embodiment, the anti-CD3 / CD20 bispecific antibody is TCB and CD20 is the second antigen. In one embodiment, the bispecific anti-CD3 / CD20 antibody is RG6026.
[0206] Embodiments of all the above aspects and embodiments: In one embodiment of all the above aspects and embodiments, an expression cassette encoding one second selection marker is located partially 5' and partially 3' of the third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising the coding sequence of one second selection marker without a start codon and a polyA signal.
[0207] In one embodiment of all the foregoing aspects and embodiments, the 5'-end portion of the expression cassette encoding one second selection marker comprises a promoter sequence operably linked to a start codon, the promoter sequence being adjacent to the expression cassette upstream (i.e., located downstream relative to the expression cassette), and the start codon being adjacent to a third recombination recognition sequence downstream (i.e., located upstream relative to the third recombination recognition sequence); and the 3'-end portion of the expression cassette encoding one second selection marker comprises a coding sequence for one second selection marker lacking a start codon, being adjacent to the third recombination recognition sequence upstream and adjacent to the expression cassette downstream.
[0208] In one embodiment of all the foregoing aspects and embodiments, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0209] In one embodiment of all the preceding aspects and embodiments, the first deoxyribonucleic acid is incorporated into a first vector and the second deoxyribonucleic acid is incorporated into a second vector.
[0210] In one embodiment of all the foregoing aspects and embodiments, each expression cassette comprises, in 5' to 3' direction, a promoter, a coding sequence, and a polyadenylation signal sequence, optionally followed by a terminator sequence.
[0211] In one embodiment of all the foregoing aspects and embodiments, The expression cassette for an antibody chain comprises, in 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; and Each expression cassette encoding a selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the selectable marker, and a polyadenylation signal sequence, and optionally, a terminator sequence.
[0212] In one embodiment of all the foregoing aspects and embodiments, the promoter is the human CMV promoter with or without intron A, the polyadenylation signal sequence is the bGH polyA site, and the terminator is the hGT terminator.
[0213] Terminator sequences prevent the generation of very long RNA transcripts by RNA polymerase II, i.e., read-through into the next expression cassette in the deoxyribonucleic acid according to the invention, and are used in the method according to the invention, i.e., the expression of one structural gene of interest is controlled by its own promoter.
[0214] Thus, the combination of a polyadenylation signal and a terminator sequence achieves efficient transcription termination. That is, the readthrough of RNA polymerase II is prevented by the presence of a double termination signal. The terminator sequence initiates complex disassembly and promotes dissociation of the RNA polymerase from the DNA template.
[0215] In one embodiment of all the foregoing aspects and embodiments, the promoter is the SV40 promoter, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence, and except for the expression cassette of the selectable marker, which is absent a terminator, the promoter is the human CMV promoter containing intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator.
[0216] In one embodiment of all the foregoing aspects and embodiments, the mammalian cell is a CHO cell. In one embodiment, the CHO cell is a CHO-K1 cell.
[0217] In one embodiment of all aspects and embodiments, the antibody is a therapeutic antibody.
[0218] In one embodiment of all the foregoing aspects and embodiments, neither the first nor the second light chain of the trivalent bispecific antibody is a common or universal light chain.
[0219] In one embodiment of all the foregoing aspects and embodiments, the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0220] In a preferred embodiment of all aspects and embodiments, exactly two deoxyribonucleic acids are included or introduced.
[0221] The individual expression cassettes in the deoxyribonucleic acid according to the invention are arranged consecutively, with the distance between the end of one expression cassette and the beginning of the following expression cassette being only a few nucleotides required for or resulting from the cloning procedure.
[0222] In one embodiment of all the foregoing aspects and embodiments, the two immediately following expression cassettes are separated by a maximum of 100 bp (i.e., a maximum of 100 base pairs (bp) from the end of each of the polyA signal or terminator sequences to the start of the following promoter element). In one embodiment, the two immediately following expression cassettes are separated by a maximum of 50 bp. In a preferred embodiment, the two immediately following expression cassettes are separated by a maximum of 30 bp. [The present invention 1001] 1. A method for producing a trivalent bispecific antibody, comprising: a) culturing mammalian cells containing deoxyribonucleic acid encoding said trivalent bispecific antibody, and b) recovering said trivalent bispecific antibody from said cells or culture medium. Including, the deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: a first expression cassette encoding a first heavy chain, a second expression cassette encoding said first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain A method comprising: [The present invention 1002] A deoxyribonucleic acid encoding a trivalent bispecific antibody, comprising, in 5' to 3' direction: a first expression cassette encoding a first heavy chain, a second expression cassette encoding said first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain Deoxyribonucleic acid, including [The present invention 1003] In the 5' to 3' direction, a first expression cassette encoding a first heavy chain, a second expression cassette encoding said first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain 10. Use of a deoxyribonucleic acid comprising the following for expression of a trivalent bispecific antibody in mammalian cells. [The present invention 1004] 1. A recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent bispecific antibody integrated into the genome of said cell, said trivalent bispecific antibody-encoding deoxyribonucleic acid comprising, in a 5' to 3' direction: a first expression cassette encoding a first heavy chain, a second expression cassette encoding said first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding the second light chain A recombinant mammalian cell comprising: [The present invention 1005] A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and four expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding said first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, a seventh expression cassette encoding the second light chain, and - a second recombination recognition sequence A composition comprising: [The present invention 1006] 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent bispecific antibody and that secretes said trivalent bispecific antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cells provided in a) two deoxyribonucleic acid compositions comprising three different recombination recognition sequences and at least seven expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding said first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, a second copy of said third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, a seventh expression cassette encoding the second light chain, and - a second recombination recognition sequence Including, the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid are identical to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of said second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases that recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express the second selection marker and secrete the trivalent bispecific antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said trivalent bispecific antibody and that secretes said trivalent bispecific antibody. [The present invention 1007] 1006. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1001 to 1006, wherein the deoxyribonucleic acid comprises an eighth expression cassette encoding the second light chain after the seventh expression cassette. [The present invention 1008] 10. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of claims 1001 to 1007, wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat). [The present invention 1009] 1008. A method for producing a trivalent bispecific antibody of the invention 1008, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, wherein one of the heavy chains further comprises the mutation S354C and the respective other heavy chain comprises the mutation Y349C (numbering according to Kabat). [The present invention 1010] A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of claims 1001 to 1009, wherein the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment VH-VL or CH1-CL. [The present invention 1011] A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of claims 1001 to 1010, wherein the first light chain is a domain-exchanged light chain VH-VL or CH1-CL. [The present invention 1012] the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; the second heavy chain comprises, from N-terminus to C-terminus, the first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site; Any of the methods for producing a trivalent bispecific antibody, deoxyribonucleic acid, or use, or recombinant mammalian cell, or composition, or method for producing a recombinant mammalian cell of the present invention 1001 to 1011. [The present invention 1013] 13. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1001, 1003, 1004 and 1006 to 1012, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus. [The present invention 1014] the deoxyribonucleic acid encoding the trivalent bispecific antibody comprises an additional expression cassette encoding a selectable marker; the expression cassette encoding the selectable marker is located partially 5' and partially 3' to the third recombination recognition sequence, the 5'-located portion of the expression cassette comprises a promoter and a start codon, the 3'-located portion of the expression cassette comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence; the 5'-located portion of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent upstream to the fourth expression cassette and the start codon is adjacent downstream to the third recombination recognition sequence, and the 3'-located portion of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon, and is adjacent upstream to the third recombination recognition sequence and downstream to the fifth expression cassette, whereby the start codon is operably linked to the coding sequence. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of the present inventions 1001 to 1005 and 1007 to 1013. [The present invention 1015] each expression cassette for an antibody chain comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, and a polyadenylation signal sequence, and optionally a terminator sequence; and each expression cassette encoding the selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the selectable marker, and a polyadenylation signal sequence, and optionally a terminator sequence; the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and no terminator is present in the expression cassette of the selectable marker; the promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator; A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any one of claims 1001 to 1014 of the present invention. [The present invention 1016] The method for producing a trivalent bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any of claims 1001, 1003, 1004, and 1006 to 1015, wherein the mammalian cell is a CHO cell. [The present invention 1017] A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of claims 1001 to 1016 of the present invention, wherein all cassettes are arranged in one direction. [The present invention 1018] 1. A method for producing a trivalent antibody, comprising: a) culturing mammalian cells containing deoxyribonucleic acid encoding the trivalent antibody; and b) recovering the trivalent antibody from the cells or culture medium. Including, the deoxyribonucleic acid encoding the trivalent antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, and a fifth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding said second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second light chain, or (4) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said first heavy chain, a sixth expression cassette encoding said second light chain, or (5) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second heavy chain, a sixth expression cassette encoding said second light chain, a seventh expression cassette encoding said second light chain, or (6) a first expression cassette encoding a first light chain, a second expression cassette encoding said first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain. A method comprising any one of the following: [The present invention 1019] A deoxyribonucleic acid encoding a trivalent antibody, comprising, in 5' to 3' direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, and a fifth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding said second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second light chain, or (4) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said first heavy chain, a sixth expression cassette encoding said second light chain, or (5) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second heavy chain, a sixth expression cassette encoding said second light chain, a seventh expression cassette encoding said second light chain, or (6) a first expression cassette encoding a first light chain, a second expression cassette encoding said first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain. Deoxyribonucleic acid, including any of the following: [The present invention 1020] In the 5' to 3' direction, (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, and a fifth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding said second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second light chain, or (4) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said first heavy chain, a sixth expression cassette encoding said second light chain, or (5) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second heavy chain, a sixth expression cassette encoding said second light chain, a seventh expression cassette encoding said second light chain, or (6) a first expression cassette encoding a first light chain, a second expression cassette encoding said first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain. Use of a deoxyribonucleic acid comprising any one of the above for expressing a trivalent antibody in a mammalian cell. [The present invention 1021] 1. A recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody integrated into the genome of said cell, said trivalent antibody-encoding deoxyribonucleic acid comprising, in a 5′ to 3′ direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, and a fifth expression cassette encoding a second light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding said second light chain, or (3) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second light chain, or (4) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said first heavy chain, a sixth expression cassette encoding said second light chain, or (5) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, a fifth expression cassette encoding said second heavy chain, a sixth expression cassette encoding said second light chain, a seventh expression cassette encoding said second light chain, or (6) a first expression cassette encoding a first light chain, a second expression cassette encoding said first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain. A recombinant mammalian cell comprising any one of the above. [The present invention 1022] A composition comprising two deoxyribonucleic acids, each of which in turn comprises three different recombination recognition sequences and five to seven expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (3) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (4) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (5) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (6) a first recombination recognition sequence, a first expression cassette encoding a first light chain, a second expression cassette encoding said first light chain, a third expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain, and a second recombination recognition sequence, or (3) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (4) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding the first heavy chain, a sixth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (5) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second light chain, a seventh expression cassette encoding the second light chain, and a second recombination recognition sequence, or (6) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence A composition comprising any one of the following: [The present invention 1023] 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent antibody and that secretes said trivalent antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cells provided in a) two deoxyribonucleic acid compositions comprising three different recombination recognition sequences and 5 to 7 expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (3) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (4) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (5) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a second heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (6) a first recombination recognition sequence, a first expression cassette encoding a first light chain, a second expression cassette encoding said first light chain, a third expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain, and a second recombination recognition sequence, or (3) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (4) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding the first heavy chain, a sixth expression cassette encoding a second light chain, and a second recombination recognition sequence, or (5) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a second light chain, a seventh expression cassette encoding the second light chain, and a second recombination recognition sequence, or (6) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid are identical to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of said second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases that recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express the second selection marker and secrete the trivalent antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said trivalent antibody and that secretes said trivalent antibody. [The present invention 1024] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, of any of claims 1018 to 1023, wherein the first heavy chain comprises the mutation T366W (numbering according to Kabat) in the CH3 domain and the second heavy chain comprises the mutations T366S, L368A, and Y407V (numbering according to Kabat) in the CH3 domain, or vice versa. [The present invention 1025] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, of the invention 1024, wherein one of the heavy chains further comprises the mutation S354C and each of the other heavy chains comprises the mutation Y349C (numbering according to Kabat). [The present invention 1026] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, of any of claims 1018 to 1025, wherein the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment. [The present invention 1027] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, of any of claims 1018 to 1026 of the present invention, wherein the first light chain is a domain-exchanged light chain VH-VL or CH1-CL. [The present invention 1028] the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, the first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of the present inventions 1018 to 1027. [The present invention 1029] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell of any of claims 1018, 1020, 1021 and 1023 to 1028, wherein the deoxyribonucleic acid is stably integrated into the genome of the mammalian cell at a single site or locus. [The present invention 1030] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1018 to 1022 and 1024 to 1029, wherein the deoxyribonucleic acid encoding the trivalent antibody comprises a further expression cassette encoding a selectable marker, and the expression cassette encoding the selectable marker is located partially 5' and partially 3' to the third recombination recognition sequence, the 5'-located portion of the expression cassette comprises a promoter and a start codon, and the 3'-located portion of the expression cassette comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence. [The present invention 1031] the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and no terminator is present in the expression cassette of the selectable marker; the promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator; A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of the present inventions 1018 to 1022 and 1024 to 1030. [The present invention 1032] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1018, 1020, 1021, and 1023 to 1031 of the present invention, wherein the mammalian cell is a CHO cell. [The present invention 1033] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of claims 1018 to 1032 of the present invention, wherein when the 5' to 3' configuration has an expression cassette encoding the first heavy chain as the first expression cassette, all cassettes are arranged in one direction. [The present invention 1034] A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1017 to 1032 of the present invention, wherein, when the 5' to 3' configuration is a first expression cassette encoding the first light chain, a second expression cassette encoding the first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding the second heavy chain, a fifth expression cassette encoding the second light chain, and a sixth expression cassette encoding the second light chain, the first expression cassette to the third expression cassette are arranged in one direction and the fourth expression cassette to the sixth expression cassette are arranged in one direction, thereby the first expression cassette to the third expression cassette are arranged in the opposite direction to the fourth expression cassette to the sixth expression cassette. [This invention 1035] 1. A method for producing a bivalent, bispecific antibody, comprising: a) culturing mammalian cells containing deoxyribonucleic acid encoding said bivalent, bispecific antibody; and b) recovering said bivalent, bispecific antibody from said cells or culture medium. Including, the deoxyribonucleic acid encoding the bivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain Including, wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat). [The present invention 1036] A deoxyribonucleic acid encoding a bivalent, bispecific antibody, comprising, in the 5' to 3' direction: a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain Including, 1. A deoxyribonucleic acid, wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat). [This invention 1037] In the 5' to 3' direction, a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain for the expression of a bivalent, bispecific antibody in a mammalian cell, comprising a deoxyribonucleic acid comprising: 1. Use wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat). [The present invention 1038] 1. A recombinant mammalian cell comprising a bivalent, bispecific antibody-encoding deoxyribonucleic acid integrated into the genome of said cell, said bivalent, bispecific antibody-encoding deoxyribonucleic acid comprising, in a 5' to 3' direction: a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding a second light chain, and a fourth expression cassette encoding a second heavy chain Including, 1. A recombinant mammalian cell, wherein the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat). [This invention 1039] A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and four expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, a first recombination recognition sequence, a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, and - a second recombination recognition sequence Including, said first heavy chain comprising the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprising the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat). [The present invention 1040] 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a bivalent, bispecific antibody and that secretes said bivalent, bispecific antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cells provided in a) two deoxyribonucleic acid compositions comprising three different recombination recognition sequences and four expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, a first recombination recognition sequence, a first expression cassette encoding a first light chain, a second expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, a third expression cassette encoding a second light chain, a fourth expression cassette encoding a second heavy chain, and - a second recombination recognition sequence Including, the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid are identical to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; the 5'-end portion and the 3'-end portion of an expression cassette encoding a second selection marker, when taken together, form a functional expression cassette for said second selection marker; introducing said first heavy chain comprising the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprising the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat), c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases that recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express the second selectable marker and secrete the bivalent, bispecific antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said bivalent, bispecific antibody and that secretes said bivalent, bispecific antibody. [This invention 1041] A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1035 to 1040, wherein one of the heavy chains further comprises the mutation S354C and the respective other heavy chain comprises the mutation Y349C (numbering according to Kabat). [The present invention 1042] A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1035 to 1041, wherein the second light chain is a domain-swapped light chain VH-CH1 after VH-VL swapping, or a domain-swapped light chain VL-CH1 after CH1-CL swapping. [This invention 1043] the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, the first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1035 to 1042 of the present invention. [This invention 1044] A method for producing a bivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell of any of claims 1035, 1037, 1038 and 1040 to 1043, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus. [This invention 1045] the deoxyribonucleic acid encoding the bivalent, bispecific antibody comprises a further expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker being located partially 5' and partially 3' to the third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal, the start codon being operably linked to the coding sequence, and the 5'-located portion of the expression cassette encoding the selectable marker comprising a promoter sequence operably linked to a start codon, thereby a method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1035 to 1039 and 1040 to 1044, wherein the promoter sequence is adjacent to the second expression cassette upstream, the start codon is adjacent to the third recombination recognition sequence downstream, and the portion located 3' of the expression cassette encoding the selection marker comprises a nucleic acid encoding a selection marker lacking a start codon, and is adjacent to the third recombination recognition sequence upstream and the third expression cassette downstream, and the start codon is operably linked to the coding sequence. [The present invention 1046] each expression cassette for an antibody chain comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, a polyadenylation signal sequence, and optionally a terminator sequence; and each expression cassette encoding the selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the selectable marker, and a polyadenylation signal sequence, and optionally a terminator sequence; the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and no terminator is present in the expression cassette of the selectable marker; the promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator; A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1035 to 1045 of the present invention. [This invention 1047] The method for producing a bivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any of claims 1035, 1037, 1038, and 1040 to 1046, wherein the mammalian cell is a CHO cell. [This invention 1048] A method for producing a bivalent, bispecific antibody, or deoxyribonucleic acid, or use, or recombinant mammalian cell, or composition, or method for producing a recombinant mammalian cell according to any of claims 1035 to 1047 of the present invention, wherein all cassettes are arranged in one direction. [This invention 1049] 1. A method for producing a multivalent, bispecific antibody, comprising: a) culturing mammalian cells containing deoxyribonucleic acid encoding said multivalent, bispecific antibody; and b) recovering the multivalent, bispecific antibody from the cells or culture medium. Including, the deoxyribonucleic acid encoding the multivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, and a sixth expression cassette encoding said first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding said first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain A method comprising any one of the following: [The present invention 1050] A deoxyribonucleic acid encoding a multivalent, bispecific antibody, comprising, in 5' to 3' direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, and a sixth expression cassette encoding said first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding said first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain Deoxyribonucleic acid, including any of the following: [This invention 1051] In the 5' to 3' direction, (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, and a sixth expression cassette encoding said first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding said first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain 10. Use of a deoxyribonucleic acid comprising any one of the above for expressing a multivalent bispecific antibody in a mammalian cell. [This invention 1052] 1. A recombinant mammalian cell comprising a deoxyribonucleic acid encoding a multivalent, bispecific antibody integrated into the genome of said cell, said multivalent, bispecific antibody-encoding deoxyribonucleic acid comprising, in a 5' to 3' direction: (1) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, and a sixth expression cassette encoding said first light chain, or (2) a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding said first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding said first light chain, a seventh expression cassette encoding the first light chain, and an eighth expression cassette encoding the first light chain A recombinant mammalian cell comprising any one of the above. [This invention 1053] A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and six or eight expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, a sixth expression cassette encoding the first light chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding said first light chain, an eighth expression cassette encoding the first light chain, and - a second recombination recognition sequence A composition comprising any one of the following: [This invention 1054] 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a multivalent, bispecific antibody and that secretes said multivalent, bispecific antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cells provided in a) two deoxyribonucleic acid compositions comprising three different recombination recognition sequences and six or eight expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, (1) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) a first recombination recognition sequence, a first expression cassette encoding a first heavy chain, a second expression cassette encoding a first light chain, a third expression cassette encoding said first light chain, a fourth expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding the first light chain, a sixth expression cassette encoding the first light chain, and a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding a first light chain, a seventh expression cassette encoding said first light chain, an eighth expression cassette encoding the first light chain, and - a second recombination recognition sequence including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid are identical to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of said second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases that recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express the second selectable marker and secrete the multivalent, bispecific antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said multivalent bispecific antibody and that secretes said multivalent bispecific antibody. [This invention 1055] 10. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, of any of claims 1049 to 1054, wherein said first heavy chain comprises the mutation T366W (numbering according to Kabat) in the CH3 domain and said second heavy chain comprises the mutations T366S, L368A, and Y407V (numbering according to Kabat) in the CH3 domain, or vice versa. [The present invention 1056] 1055. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to the invention, wherein one of the heavy chains further comprises the mutation S354C and the respective other heavy chain comprises the mutation Y349C (numbering according to Kabat). [This invention 1057] A method for producing a multivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any of claims 1049 to 1056, wherein the first light chain is a domain-exchanged light chain VH-VL or CH1-CL. [This invention 1058] the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a first light chain variable domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a second heavy chain variable domain; and - the first light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; A method for producing a polyvalent bispecific antibody of any of the present inventions 1049 to 1057, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell. [This invention 1059] 1058. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell of any of claims 1049, 1051, 1052 and 1054 to 1058, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus. [The present invention 1060] the deoxyribonucleic acid encoding the multivalent, bispecific antibody comprises a further expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker being located partially 5' and partially 3' to the third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal, the start codon being operably linked to the coding sequence, and the 5'-located portion of the expression cassette encoding the selectable marker comprising a promoter sequence operably linked to a start codon, whereby the promoter sequence is upstream of the third recombination recognition sequence. the start codon is adjacent to the third recombination recognition sequence upstream and adjacent to the fourth expression cassette or the fifth expression cassette, respectively, and the start codon is operably linked to the coding sequence, and the 3'-located portion of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon, and is adjacent to the third recombination recognition sequence upstream and adjacent to the fourth expression cassette or the fifth expression cassette, respectively, and the start codon is operably linked to the coding sequence, and [The present invention 1061] each expression cassette for an antibody chain comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, and a polyadenylation signal sequence, and optionally a terminator sequence; and each expression cassette encoding the selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the selectable marker, and a polyadenylation signal sequence, and optionally a terminator sequence; the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and no terminator is present in the expression cassette of the selectable marker; the promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator; A method for producing a multivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1049 to 1060. [The present invention 1062] The method for producing a polyvalent bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any of claims 1049, 1051, 1052, and 1054 to 1061, wherein the mammalian cell is a CHO cell. [The present invention 1063] A method for producing a multivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any of claims 1049 to 1062, wherein all expression cassettes are arranged in one direction. [The present invention 1064] 1. A method for producing a recombinant mammalian cell that contains a deoxyribonucleic acid encoding a polypeptide and that secretes said polypeptide, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, wherein said recombination recognition sequences are all different, and said mammalian cell does not comprise DNA encoding Cre recombinase; b) introducing into the cells provided in a) two deoxyribonucleic acid compositions comprising three different recombination recognition sequences and 1 to 8 expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction: a first recombination recognition sequence, one or more expression cassettes, - a 5'-end portion of an expression cassette encoding a second selection marker, and - a first copy of a third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction: - a second copy of a third recombination recognition sequence, - a 3'-end portion of said expression cassette encoding a second selection marker, one or more expression cassettes, and - a second recombination recognition sequence Includes the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid are identical to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; the 5'-end portion and the 3'-end portion of the expression cassette encoding said one second selection marker, when taken together, form a functional expression cassette of said one second selection marker; introducing the deoxyribonucleic acid, wherein the deoxyribonucleic acid does not contain DNA encoding Cre recombinase; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing Cre recombinase mRNA as the sole source of Cre recombinase, introducing said Cre recombinase, which recognizes said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express the second selectable marker and secrete the polypeptide. thereby producing a recombinant mammalian cell which contains deoxyribonucleic acid encoding said polypeptide and which secretes said polypeptide. [This invention 1065] 1064. The method of claim 1064, wherein said Cre mRNA encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 20. [The present invention 1066] 1065. The method of claim 1064, wherein said Cre mRNA comprises the nucleotide sequence of SEQ ID NO: 21 or a codon usage optimized variant thereof. [This invention 1067] 1067. The method of any of claims 1064 to 1066, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus. [The present invention 1068] the deoxyribonucleic acid encoding the polypeptide comprises at least four expression cassettes; - the first recombination recognition sequence is located 5' to the 5'-most (i.e., first) expression cassette, - the second recombination recognition sequence is located 3' to the 3'-most expression cassette, a third recombination recognition sequence, - between the first recombination recognition sequence and the second recombination recognition sequence, and between two of said expression cassettes Located in and The recombination recognition sequences are all different. Any of methods 1064 to 1067 of the present invention. [The present invention 1069] 1069. The method of any of claims 1064 to 1068, wherein said deoxyribonucleic acid encoding said polypeptide comprises an additional expression cassette encoding a selectable marker. [The present invention 1070] Any of the methods of claims 1064 to 1069, wherein the deoxyribonucleic acid encoding the polypeptide comprises a further expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker being located partially 5' and partially 3' to the third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence. [This invention 1071] The method of any of claims 1064 to 1070, wherein the weight ratio of Cre mRNA to the mixture of the first vector and the second vector is within the range of 1:3 to 2:1. [This invention 1072] The method of any of claims 1064 to 1071, wherein the weight ratio of Cre mRNA to the mixture of the first vector and the second vector is about 1:5. [This invention 1073] each of said expression cassettes comprising, in the 5' to 3' direction, a promoter, a coding sequence, and a polyadenylation signal sequence, optionally followed by a terminator sequence; the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and no terminator is present in the expression cassette of the selectable marker; the promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator; Any of the methods of 1064 to 1072 of the present invention. [This invention 1074] The method of any one of claims 1064 to 1073, wherein the mammalian cells are CHO cells. [This invention 1075] the polypeptide is a heterotetramer comprising a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain, and the deoxyribonucleic acid comprises four expression cassettes; the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; Any of the methods of 1064 to 1074 of the present invention. [This invention 1076] the polypeptide is a heterotetramer comprising a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain, the deoxyribonucleic acid comprising four expression cassettes; and the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the second heavy chain comprises, from N-terminus to C-terminus, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; Any of the methods of 1064 to 1074 of the present invention. [This invention 1077] the polypeptide is a heterotetramer comprising a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain, and the deoxyribonucleic acid comprises four expression cassettes; the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site; Any of the methods of 1064 to 1074 of the present invention. [This invention 1078] The method of any one of claims 1064 to 1077, wherein the first recombinase recognition sequence is L3, the second recombinase recognition sequence is 2L, and the third recombinase recognition sequence is LoxFas. [This invention 1079] Use of Cre-recombinase mRNA to increase the number of recombinant mammalian cells containing a deoxyribonucleic acid encoding a polypeptide or protein of interest that is stably integrated into a single site in the genome of said recombinant mammalian cells by targeted integration. [The present invention 1080] The use of invention 1079, wherein said recombinant cell further secretes said polypeptide of interest into a culture medium when cultured in said culture medium. DETAILED DESCRIPTION OF THE INVENTION
[0223] Detailed Description of Embodiments of the Invention The present invention is based, at least in part, on the discovery that the use of predetermined and specific expression cassette configurations for the expression of trivalent bispecific antibodies, which are complex molecules comprising different polypeptides, i.e., heteromultimers, results in the efficient expression and production of trivalent bispecific antibodies in mammalian cells, such as CHO cells.
[0224] The present invention is based, at least in part, on the discovery that dual recombinase-mediated cassette exchange (RMCE) can be used to produce recombinant mammalian cells, such as recombinant CHO cells, whereby a predetermined and specific expression cassette sequence is integrated into the genome, resulting in efficient expression and production of a trivalent bispecific antibody. This integration occurs at a specific site in the genome of the mammalian cell by targeted integration. This makes it possible to control the expression ratio of the different polypeptides of the heteromultimeric trivalent bispecific antibody relative to each other. This results in efficient expression, accurate assembly, and successful secretion of a correctly folded and assembled trivalent bispecific antibody with high expression yields.
[0225] The present invention is based, at least in part, on the discovery that the use of predetermined and specific expression cassette configurations for the expression of trivalent antibodies (e.g., TCB), which are complex molecules comprising different polypeptides, i.e., heteromultimers, results in the efficient expression and production of trivalent antibodies (e.g., TCB) in mammalian cells, such as CHO cells.
[0226] The present invention is based, at least in part, on the discovery that dual recombinase-mediated cassette exchange (RMCE) can be used to produce recombinant mammalian cells, such as recombinant CHO cells, whereby a predetermined and specific expression cassette sequence is integrated into the genome, resulting in efficient expression and production of a trivalent antibody (e.g., TCB). This integration is induced at a specific site in the genome of the mammalian cell by targeted integration. This makes it possible to control the expression ratio of different polypeptides of a heteromultimeric trivalent antibody (e.g., TCB) relative to each other. This results in efficient expression, accurate assembly, and successful secretion of a correctly folded and assembled trivalent antibody (e.g., TCB) with high expression yields.
[0227] The present invention is based, at least in part, on the discovery that the use of predetermined and specific expression cassette configurations for the expression of bivalent, bispecific antibodies, which are complex molecules comprising different polypeptides, i.e., heteromultimers, results in the efficient expression and production of bivalent, bispecific antibodies in mammalian cells, such as CHO cells.
[0228] The present invention is based, at least in part, on the discovery that dual recombinase-mediated cassette exchange (RMCE) can be used to produce recombinant mammalian cells, such as recombinant CHO cells, whereby a predetermined and specific expression cassette sequence is integrated into the genome, resulting in efficient expression and production of bivalent bispecific antibodies. This integration occurs at a specific site in the genome of the mammalian cell by targeted integration. This makes it possible to control the expression ratio of the different polypeptides of the heteromultimeric bivalent bispecific antibody relative to each other. This results in efficient expression, accurate assembly, and successful secretion of correctly folded and assembled bivalent bispecific antibodies with high expression yields.
[0229] The present invention is based, at least in part, on the discovery that using Cre mRNA as the sole source of Cre recombinase, compared with, for example, Cre DNA (Cre plasmid), can improve the number of clones obtained by targeted integration. More specifically, after a selection period, the absolute number of clones in a CRE mRNA-generated recombinant cell pool was found to be greater than that in a CRE plasmid-generated recombinant cell pool (see Example 10 and Figures 2, 3, and 4). Therefore, by using CRE mRNA instead of a CRE plasmid, a recombinant cell pool with greater size and heterogeneity is produced. Without being bound by this theory, it is assumed that this increases the probability of identifying recombinant cell clones with high titers and good product quality. Furthermore, the increase in the number of recombinant cell clones from a CRE mRNA-generated pool is stable compared to a CRE plasmid-generated cell pool.
[0230] I. Definition Useful methods and techniques for practicing the present invention are described, for example, in Ausubel, FM (ed.), Current Protocols in Molecular Biology, Volumes I to III (1997); Glover, ND, and Hames, BD, ed., DNA Cloning: A Practical Approach, Volumes I and II (1985), Oxford University Press; Freshney, RI (ed.), Animal Cell Culture - a practical approach, IRL Press Limited (1986); Watson, JD, et al., Recombinant DNA, Second Edition, CHSL Press (1992); Winnacker, EL, From Genes to Clones; NY, VCH Publishers (1987); Celis, J., ed., Cell Biology, Second Edition, Academic Press (1998); Freshney, RI, Culture of Animal Cells: A Manual of Basic Technique, second edition, Alan R. Liss, Inc., NY (1987).
[0231] The use of recombinant DNA technology allows the production of derivatives of nucleic acids. Such derivatives can be modified at individual or several nucleotide positions, for example, by substitution, alteration, replacement, deletion, or insertion. Modification or derivatization can be carried out, for example, by site-directed mutagenesis. Such modifications can be easily carried out by those skilled in the art (see, for example, Sambrook, J., et al., Molecular Cloning: A laboratory manual (1999) Cold Spring Harbor Laboratory Press, New York, USA; Hames, B.D., and Higgins, S.G., Nucleic acid hybridization—a practical approach (1985) IRL Press, Oxford, England).
[0232] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include the plural unless the context clearly dictates otherwise. Thus, for example, a reference to a "cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth. Similarly, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein. It should also be noted that the terms "comprising," "including," and "having" can be used interchangeably.
[0233] The term "about" refers to a range of ±20% of the preceding numerical value. In one embodiment, the term about refers to a range of ±10% of the preceding numerical value. In one embodiment, the term about refers to a range of ±5% of the preceding numerical value.
[0234] The term "Cre-recombinase" refers to a tyrosine recombinase that catalyzes site-specific recombination between LoxP sites using a topoisomerase I-like mechanism. The enzyme has a molecular weight of approximately 38 kDa and consists of 343 amino acid residues. It is a member of the integrase family. Cre recombinase has the following amino acid sequence: TIFF2024167256000002.tif48142 and Cre mRNA has the following sequence: TIFF2024167256000003.tif137143 or its codon-optimized variants.
[0235] The term "comprising" also encompasses the term "consisting of."
[0236] As used herein, the term "CD20-TCB" refers to a CD20-targeted TCB (CD20-TCB; RG6026; an anti-CD3 / CD20 antibody in a TCB format), which has a long half-life and high potency enabled by high-avidity bivalent binding to CD20 and a head-to-tail orientation of the B and T cell binding domains in a previously characterized 2:1 TCB molecule format (see, e.g., Bacac, M., et al., Clin. Cancer Res. 22 (2016) 3286-3297; Bacac, M., et al., Oncoimmunology 5 (2016) e1203498).
[0237] The term "mammalian cell comprising an exogenous nucleotide sequence" encompasses cells into which one or more exogenous nucleic acids have been introduced and which are intended to be the starting point for subsequent genetic modification, including the progeny of such cells. Thus, the term "mammalian cell comprising an exogenous nucleotide sequence" encompasses cells comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of the mammalian cell, the exogenous nucleotide sequence comprising at least one first recombination recognition sequence and at least one second recombination recognition sequence (the recombinase recognition sequences are different) flanked by at least one first selectable marker. In one embodiment, a mammalian cell comprising an exogenous nucleotide sequence is a cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of the host cell, the exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence flanked by at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and the recombination recognition sequences are all different.
[0238] The term "nuclear localization sequence" as used herein refers to an amino acid sequence containing multiple copies of the positively charged amino acid residues arginine and / or lysine. Polypeptides containing the sequence are identified by cells for introduction into the cell nucleus. Exemplary nuclear localization sequences are PKKKRKV (SEQ ID NO: 33; SV40 large T antigen), KR[PAATKKAGQA]KKKK (SEQ ID NO: 34, SV40 nucleoplasmin), MSRRRKANPTKLSENAKKLAKEVEN (SEQ ID NO: 35; Caenorhabditis elegans EGL-13), PAAKRVKLD (SEQ ID NO: 36, human c-myc), and KLKIKRPVK (SEQ ID NO: 37, Escherichia coli end-utilization substance protein). Other nuclear localization sequences can be easily identified by those skilled in the art.
[0239] As used herein, the term "recombinant cell" refers to a cell after final genetic modification, for example, a cell that expresses a polypeptide of interest and can be used for the production of said polypeptide of interest on any scale. For example, a "mammalian cell containing an exogenous nucleotide sequence" that has been subjected to recombinase-mediated cassette exchange (RMCE), thereby introducing the coding sequence of the polypeptide of interest into the genome of the host cell, is a "recombinant cell". Although this cell can still undergo further RMCE reactions, it is not intended to do so.
[0240] The term "LoxP site" refers to a 34-bp nucleotide sequence consisting of two palindromic 13-bp sequences at the ends (ATAACTTCGTATA (SEQ ID NO: 22) and TATACGAAGTTAT (SEQ ID NO: 23) respectively) and a central 8-bp core (asymmetric) spacer sequence. The core spacer sequence determines the orientation of the LoxP site. Depending on the relative orientation and position of the LoxP sites relative to each other, the intervening DNA is either excised (LoxP sites oriented in the same direction) or inverted (LoxP sites oriented in the opposite direction). The term "floxed" refers to the DNA sequence located between two LoxP sites. When two floxed sequences, i.e., a target floxed sequence in the genome and a floxed sequence in the donor nucleic acid, are present, both sequences can be exchanged with each other. This is called "recombinase-mediated cassette exchange."
[0241] Exemplary LoxP sites are shown in the table below: TIFF2024167256000004.tif53128
[0242] Both "mammalian cells containing an exogenous nucleotide sequence" and "recombinant cells" are "transformed cells." This term includes the primary transformed cell and progeny derived therefrom, regardless of the number of transfers. The progeny may not, for example, have completely identical nucleic acid content as the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included.
[0243] An "isolated" composition is one that has been separated from a component of its natural environment. In some embodiments, the composition is purified to greater than 95% or 99% purity, as determined, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis, CE-SDS) or chromatography (e.g., size exclusion chromatography, or ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman, S. et al., J. Chrom. B 848 (2007) 79-87.
[0244] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. Isolated nucleic acid includes a nucleic acid molecule contained within a cell that normally contains the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0245] An "isolated" polypeptide or antibody refers to a polypeptide or antibody molecule that has been separated from a component of its natural environment.
[0246] The term "integration site" refers to a nucleic acid sequence within a cell's genome into which an exogenous nucleotide sequence is inserted. In certain embodiments, the integration site is between two adjacent nucleotides in the cell's genome. In certain embodiments, the integration site comprises a stretch of nucleotide sequence. In certain embodiments, the integration site is located within a specific locus in the genome of a mammalian cell. In certain embodiments, the integration site is within an endogenous gene of a mammalian cell.
[0247] The terms "vector" or "plasmid," which can be used interchangeably, as used herein refer to a nucleic acid molecule capable of propagating another nucleic acid to which it has been linked. The term encompasses both autonomously replicating nucleic acid structures and vectors that have integrated into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0248] The term "binding" refers to the binding of a binding site to its target. For example, the binding of an antibody binding site comprising an antibody heavy chain variable domain and an antibody light chain variable domain to their respective antigens. This binding can be measured, for example, using a BIAcore® assay (GE Healthcare, Uppsala, Sweden). That is, the term "binding (to an antigen)" refers to the binding of an antibody to an antigen(s) in an in vitro assay. In one embodiment, binding is determined in a binding assay in which the antibody is bound to a surface and the binding of the antigen to the antibody is measured by surface plasmon resonance (SPR). Binding refers to, for example, the binding of an antibody to an antigen within a range of 10 -8 M or less, in some embodiments 10 -13 ~10 -8 M, in some embodiments, 10 -13 ~10 -9 Binding affinity (K D The term "bind" also includes the term "specifically bind."
[0249] For example, in one possible embodiment of a BIAcore® assay, the antigen is bound to a surface and the binding of the antibody, i.e., its binding site(s), is measured by surface plasmon resonance (SPR). The affinity of binding is measured by the term k a (association constant: rate constant for association to form a complex), k d (dissociation constant, rate constant for dissociation of the complex), and K D (k d / k aAlternatively, the binding signal of an SPR sensorgram can be directly compared to the response signal of a reference in terms of resonance signal height and dissociation behavior.
[0250] The term "binding site" refers to any proteinaceous entity that exhibits binding specificity to a target. It may be, for example, a receptor, a receptor ligand, anticalin, an affibody, an antibody, etc. Thus, as used herein, the term "binding site" refers to a polypeptide that is capable of specifically binding to or being specifically bound by a second polypeptide.
[0251] As used herein, the term "selection marker" refers to a gene that allows cells carrying a gene to be specifically selected or specifically eliminated in the presence of a corresponding selection agent. For example, but not limited to, a selection marker can allow host cells transformed with the selection marker gene to be positively selected in the presence of the respective selection agent (selective culture conditions), while untransformed host cells cannot grow or survive under selective culture conditions. A selection marker can be positive, negative, or bifunctional. A positive selection marker can allow for the selection of cells carrying the marker, while a negative selection marker can allow for the selective elimination of cells carrying the marker. A selection marker can confer drug resistance or complement a metabolic or catabolic defect in the host cell. In prokaryotic cells, genes that confer resistance to ampicillin, tetracycline, kanamycin, or chloramphenicol, among others, can be used. Resistance genes useful as selectable markers in eukaryotic cells include, but are not limited to, genes for aminoglycoside phosphotransferase (APH) (e.g., hygromycin phosphotransferase (HYG), neomycin, and G418 APH), dihydrofolate reductase (DHFR), thymidine kinase (TK), glutamine synthetase (GS), asparagine synthetase, tryptophan synthetase (indole), histidinol dehydrogenase (histidinol D), and genes encoding resistance to puromycin, blasticidin, bleomycin, phleomycin, chloramphenicol, zeocin, and mycophenolic acid. Additional marker genes are described in WO 92 / 08796 and WO 94 / 28143.
[0252] In addition to facilitating selection in the presence of a corresponding selection agent, a selection marker may alternatively be a molecule not normally present in cells, such as green fluorescent protein (GFP), enhanced GFP (eGFP), synthetic GFP, yellow fluorescent protein (YFP), enhanced YFP (eYFP), cyan fluorescent protein (CFP), mPlum, mCherry, tdTomato, mStrawberry, J-red, DsRed monomer, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, mCFPm, Cerulean, and T-Sapphire. For example, cells expressing such molecules can be distinguished from cells that do not harbor the gene based on the detection or absence, respectively, of fluorescence emitted by the encoded polypeptide.
[0253] As used herein, the term "operably linked" refers to the juxtaposition of two or more components, wherein the components are in a relationship permitting them to function in their intended manner. For example, a promoter and / or enhancer is operably linked to a coding sequence if it acts to regulate the transcription of the coding sequence. In certain embodiments, "operably linked" DNA sequences are contiguous and adjacent on a single chromosome. In certain embodiments, for example, where necessary to join two protein-encoding regions, such as a secretory leader and a polypeptide, the sequences are contiguous, adjacent, and in the same reading frame. In certain embodiments, an operably linked promoter may be located upstream of and adjacent to the coding sequence. In certain embodiments, for example, with respect to an enhancer sequence that regulates expression of a coding sequence, two components may be operably linked even if they are not adjacent. An enhancer is operably linked to a coding sequence if it increases transcription of the coding sequence. An operably linked enhancer may be located upstream, within, or downstream of the coding sequence, and may be located a substantial distance from the promoter of the coding sequence. Operable linkage can be achieved by recombinant methods known in the art, for example, using PCR and / or by ligation at convenient restriction sites. If convenient restriction sites do not exist, synthetic oligonucleotide adapters or linkers can be used according to conventional methods. An internal ribosome entry site (IRES) is operably linked to an open reading frame (ORF) if the IRES is capable of initiating translation of the ORF at an internal location in a 5'-end-independent manner.
[0254] As used herein, the term "adjacent" means that the first nucleotide sequence is located at either the 5'-end or 3'-end of the second nucleotide sequence, or at both ends.Adjacent nucleotide sequence can be adjacent to the second nucleotide sequence, or at a specified distance from the second nucleotide sequence.There is no specific limit to the length of adjacent nucleotide sequence.For example, adjacent sequence can be a few base pairs or several thousand base pairs.
[0255] As used herein, the term "exogenous" refers to a nucleotide sequence that is not native to a particular cell and is introduced into the cell by a DNA delivery method, such as transfection, electroporation, or transformation. Thus, an exogenous nucleotide sequence is an artificial sequence, and this artifact can result, for example, from the combination of subsequences of different origins (for example, the combination of a recombinase recognition sequence with an SV40 promoter and a green fluorescent protein coding sequence is an artificial nucleic acid), or from partial deletion or nucleic acid base mutation of a sequence (for example, a sequence or cDNA encoding only the extracellular domain of a membrane-bound receptor). The term "endogenous" refers to a nucleotide sequence that originates from a cell. An "exogenous" nucleotide sequence may have an "endogenous" counterpart with the same base composition, but an "exogenous" sequence is introduced into a cell by, for example, recombinant DNA technology.
[0256] antibody General information relating to the nucleotide sequences of human immunoglobulin light and heavy chains is provided in Kabat, EA, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991).
[0257] The term "heavy chain" is used herein in its original sense, i.e., to refer to the two larger polypeptide chains of the four polypeptide chains that form an antibody (see, e.g., Edelman, GM and Gally JA, J. Exp. Med. 116 (1962) 207-227). In this context, the term "larger" can refer to either molecular weight, length, or number of amino acids. The term "heavy chain" is independent of the sequence and number of individual antibody domains present therein. It is assigned solely on the basis of the molecular weight of the respective polypeptide.
[0258] The term "light chain" is used herein in its original sense, i.e., to refer to the two smaller polypeptide chains of the four polypeptide chains that form an antibody (see, e.g., Edelman, GM and Gally JA, J. Exp. Med. 116 (1962) 207-227). In this context, the term "smaller" can refer to either molecular weight, length, or number of amino acids. The term "light chain" is independent of the sequence and number of individual antibody domains present therein. It is assigned solely based on the molecular weight of the respective polypeptide.
[0259] As used herein, the amino acid positions of all heavy and light chain constant regions and domains are numbered according to the Kabat numbering system as set forth in Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), and is referred to herein as "Kabat numbering." Specifically, the Kabat numbering system of Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see pages 647-660) is used for the light chain constant domains CL of kappa and lambda isotypes, and the Kabat EU index numbering system of Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) (see pages 661-723) is used for the heavy chain constant domains (CH1, hinge, CH2, and CH3, which are further defined herein by reference to "Kabat EU index numbering" in this case).
[0260] As used herein, the term "antibody" is used in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, full length antibodies, monoclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody-antibody fragment-fusions.
[0261] The term "native antibody" refers to naturally occurring immunoglobulin molecules with various structures. For example, native IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons, comprising two identical light chains and two identical heavy chains disulfide-linked. From N- to C-terminus, each heavy chain contains a heavy chain variable region (VH) followed by three heavy chain constant domains (CH1, CH2, CH3), which position a hinge region between the first heavy chain constant domain and the second heavy chain constant domain. Similarly, from N- to C-terminus, each light chain contains a light chain variable region (VL) followed by a light chain constant domain (CL). Based on the amino acid sequence of their constant domains, antibody light chains can be assigned to one of two types, called κ (kappa) or λ (lambda).
[0262] The term "full-length antibody" refers to an antibody with a structure substantially similar to that of a native antibody. A full-length antibody comprises, from N- to C-terminal, two or more full-length antibody light chains, each comprising a variable region and a constant domain, and two full-length antibody heavy chains, each comprising, from N- to C-terminal, a variable region, a first constant domain, a hinge region, a second constant domain, and a third constant domain. In contrast to native antibodies, full-length antibodies may contain additional immunoglobulin domains, such as one or more additional scFvs, or heavy or light chain Fab fragments, or scFabs conjugated to one or more of the ends of different chains of the full-length antibody, but may only contain a single fragment at each end. These conjugates are also encompassed by the term full-length antibody.
[0263] The term "antibody combining site" refers to a pair of heavy and light chain variable domains. To ensure proper binding to an antigen, these variable domains are cognate variable domains, i.e., belong together. An antibody combining site comprises at least three HVRs (e.g., in the case of a VHH) or three to six HVRs (e.g., in the case of a naturally occurring, i.e., conventional antibody with a VH / VL pair). Generally, the amino acid residues of an antibody involved in antigen binding form the combining site. These residues are usually contained in the pair of antibody light chain variable domains corresponding to the antibody heavy chain variable domain. An antibody antigen-binding site comprises amino acid residues from "hypervariable regions" or "HVRs." "Framework" or "FR" regions are variable domain regions other than the hypervariable region residues as defined herein. Thus, the light and heavy chain variable domains of an antibody comprise, from N- to C-terminus, the regions FR1, HVR1, FR2, HVR2, FR3, HVR3, and FR4. In particular, the HVR3 region of the heavy chain variable domain is the region that contributes most to antigen binding and defines the binding specificity of the antibody. A "functional binding site" can specifically bind to its target. The term "specifically bind" refers to the binding of a binding site to a target in an in vitro assay, in one embodiment, in a binding assay. Such a binding assay can be any assay as long as a binding event can be detected. For example, a binding assay in which an antibody is bound to a surface and the binding of antigen(s) to the antibody is measured by surface plasmon resonance (SPR). Alternatively, a bridging ELISA can be used.
[0264] The term "hypervariable region" or "HVR", as used herein, refers to each region of an antibody variable domain comprising stretches of amino acid residues that are hypervariable sequences ("complementarity determining regions" or "CDRs") and / or form structurally defined loops ("hypervariable loops") and / or contain residues that contact the antigen ("antigen contacts"). Typically, antibodies contain six HVRs: three in the heavy chain variable domain VH (H1, H2, H3) and three in the light chain variable domain VL (L1, L2, L3).
[0265] HVR includes: (a) Hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia, C. and Lesk, A. M., J. Mol. Biol. 196 (1987) 901-917); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242); (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996)); and (d) A combination of (a), (b), and / or (c) comprising amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).
[0266] Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al.
[0267] The "class" of an antibody refers to the type of constant domain or constant region, preferably the Fc region, possessed by the heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, some of which may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0268] The term "heavy chain constant region" refers to the region of an immunoglobulin heavy chain containing the constant domains, i.e., the CH1 domain, hinge region, CH2 domain, and CH3 domain in the case of native immunoglobulins, or the first constant domain, hinge region, second constant domain, and third constant domain in the case of full-length immunoglobulins. In one embodiment, a human IgG heavy chain constant region extends from Ala118 to the carboxyl-terminus Ala118 of the heavy chain (numbering according to the Kabat EU index). However, the C-terminal lysine (Lys447) of the constant region may or may not be present (numbering according to the Kabat EU index). The term "constant region" refers to a dimer containing two heavy chain constant regions that can be covalently linked to each other via hinge region cysteine residues that form interchain disulfide bonds.
[0269] The term "heavy chain Fc region" refers to the C-terminal region of an immunoglobulin heavy chain, including the hinge region (middle and lower hinge regions), the second constant domain, e.g., the CH2 domain, and at least a portion of the third constant domain, e.g., the CH3 domain. In one embodiment, a human IgG heavy chain Fc region extends from Asp221 or Cys226 or Pro230 to the carboxyl terminus of the heavy chain (numbering according to the Kabat EU index). Thus, the Fc region is smaller than the constant region, but is located at the same C-terminal end. However, the C-terminal lysine (Lys447) of the heavy chain region may or may not be present (numbering according to the Kabat EU index). The term "Fc region" refers to a dimer comprising two heavy chain Fc regions, which can be covalently linked to each other via hinge region cysteine residues that form interchain disulfide bonds.
[0270] The constant region of an antibody, more precisely the Fc region (and similar constant regions), is directly involved in complement activation, C1q binding, C3 activation, and Fc receptor binding. The effect of an antibody on the complement system depends on the specific conditions, but binding to C1q is triggered by a defined binding site in the Fc region. Such binding sites are known in the prior art and are described, for example, in Lukas, TJ, et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R., and Cebra, JJ, Mol. Immunol. 16 (1979) 907-917; Burton, DR, et al., Nature 288 (1980) 338-344; Thommesen, JE, et al., Mol. Immunol. 37 (2000) 995-1004; Idusogie, EE, et al., J. Immunol. 164 (2000) 4178-4184; Hezareh, M., et al., J. Virol. 75 (2001) 12161-12168; Morgan, A., et al., Immunology 86 (1995) 319-324, and European Patent No. 0 307 434. Such binding sites are, for example, L234, L235, D270, N297, E318, K320, K322, P331, and P329 (numbering according to the EU index of Kabat). Antibodies of the subclasses IgG1, IgG2, and IgG3 typically exhibit complement activation, C1q binding, and C3 activation, whereas IgG4 does not activate the complement system, does not bind C1q, and does not activate C3. The term "Fc region of an antibody" is well known to those skilled in the art and is defined based on papain cleavage of an antibody.
[0271] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind to the same epitope, except for possible variant antibodies that contain, for example, naturally occurring mutations or that arise during production of the monoclonal antibody preparation, and such variants are generally present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and should not be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies may be produced by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci.
[0272] The term "valency," as used herein, refers to the presence of a particular number of binding sites in an antibody. Thus, the terms "bivalent," "tetravalent," and "hexavalent" refer to the presence of two, four, and six binding sites, respectively, in an antibody.
[0273] A "monospecific antibody" refers to an antibody that has a single binding specificity, i.e., that binds preferentially to one antigen. Monospecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2), or combinations thereof (e.g., full-length antibodies with additional scFv or Fab fragments). Monospecific antibodies need not be monovalent; that is, they may contain two or more binding sites that specifically bind to one antigen. For example, naturally occurring antibodies are monospecific but bivalent.
[0274] A "multispecific antibody" refers to an antibody that has binding specificities for at least two different epitopes on the same antigen or two different antigens. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies), or combinations thereof (e.g., full-length antibodies with additional scFv or Fab fragments). Multispecific antibodies are at least bivalent, i.e., contain two antigen-binding sites. Multispecific antibodies are also at least bispecific. Thus, trivalent bispecific antibodies are the simplest form of multispecific antibodies. Engineered antibodies with two, three, or more (e.g., four) functional antigen-binding sites have been reported (see, e.g., U.S. Patent Application Publication No. 2002 / 0004587).
[0275] In certain embodiments, the antibody is a multispecific antibody, for example, at least a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificities for at least two different antigens or epitopes. In certain embodiments, one of the binding specificities is for a first antigen, and the other is for a different second antigen. In certain embodiments, a multispecific antibody can bind to two different epitopes of the same antigen. Multispecific antibodies can also be used to localize cytotoxic agents to cells expressing the antigen.
[0276] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein, C. and Cuello, A.C., Nature 305 (1983) 537-540; WO 93 / 08829; and Traunecker, A., et al., EMBO J. 10 (1991) 3655-3659) and "knobs-in-holes" engineering (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can also be produced by manipulating electrostatic steering effects to create antibody Fc-heterodimeric molecules (WO 2009 / 089004), cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan, M., et al., Science, 229 (1985) 81-83), using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny, SA, et al., J. Immunol. 148 (1992) 1547-1553; using specific techniques for making bispecific antibody fragments (see, e.g., Holliger, P., et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448), and using single-chain Fv (scFv) dimers (see, e.g., Gruber, M., et al., J. Immunol. 148 (1992) 1547-1553 ...). al., J. Immunol. 152 (1994) 5368-5374, and for example, by preparing trispecific antibodies as described in Tutt, A., et al., J. Immunol. 147 (1991) 60-69).
[0277] The antibody or fragment may also be a multispecific antibody as described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792 or WO 2010 / 145793.
[0278] The antibody or fragment thereof may also be a multispecific antibody as disclosed in WO 2012 / 163520.
[0279] Bispecific antibodies are generally antibody molecules that specifically bind to two different, non-overlapping epitopes on the same antigen or to two epitopes on different antigens.
[0280] In this context, the term "non-overlapping" indicates that amino acid residues contained within the first paratope of a bispecific Fab are not contained within the second paratope, and that amino acids contained within the second paratope of a bispecific Fab are not contained within the first paratope.
[0281] The "knob-into-hole" dimerization module and its use in antibody engineering is described in Carter P.; Ridgway JBB; Presta LG: Immunotechnology, Volume 2, Number 1, February 1996, pp. 73-73(1).
[0282] The CH3 domains of antibody heavy chains can be modified using the "knob-into-hole" technique. This technique is described in detail, with some examples, in WO 96 / 027011, Ridgway, JB, et al., Protein Eng. 9 (1996) 617-621, and Merchant, AM, et al., Nat. Biotechnol. 16 (1998) 677-681. This method involves modifying the interaction surfaces of two CH3 domains to increase heterodimerization of these two CH3 domains, thereby increasing heterodimerization of polypeptides containing them. Each of the two CH3 domains (of the two heavy chains) can be a "knob," and the other a "hole." The introduction of disulfide bridges further stabilizes the heterodimer (Merchant, AM, et al., Nature Biotech. 16 (1998) 677-681; Atwell, S., et al., J. Mol. Biol. 270 (1997) 26-35) and increases the yield.
[0283] The mutation T366W in the CH3 domain (of an antibody heavy chain) is designated as a "knob mutation" or "mutated knob," and the mutations T366S, L368A, and Y407V in the CH3 domain (of an antibody heavy chain) are designated as "hole mutations" or "mutated hole" (numbering according to the EU index of Kabat). Additional interchain disulfide bridges between CH3 domains (Merchant, AM et al., Nature Biotech. 16 (1998) 677-681) can also be used, for example, by introducing a S354C mutation in the CH3 domain of a heavy chain with a "knob mutation" (designated as a "knob-cys-mutation" or "mutated knob-cys") and a Y349C mutation in the CH3 domain of a heavy chain with a "hole mutation" (designated as a "hole-cys-mutation" or "mutated hole-cys") (numbering according to the EU index of Kabat).
[0284] The term "domain crossover" as used herein refers to deviations in domain sequence from that of the native antibody in that in a pair of an antibody heavy chain VH-CH1 fragment and its corresponding cognate antibody light chain, i.e., antibody Fab (fragment-antigen binding), at least one heavy chain domain is replaced by the corresponding light chain domain, or vice versa. There are three general types of domain crossovers: (i) crossovers between CH1 and CL domains, where the domain crossover in the light chain results in a VL-CH1 domain sequence and the domain crossover in the heavy chain fragment results in a VH-CL domain sequence (or a full-length antibody heavy chain having a VH-CL-hinge-CH2-CH3 domain sequence); (ii) domain crossovers between VH and VL domains, where the domain crossover in the light chain results in a VH-CL domain sequence and the domain crossover in the heavy chain fragment results in a VL-CH1 domain sequence; and (iii) domain crossovers between a complete light chain (VL-CL) and a complete VH-CH1 heavy chain fragment ("Fab crossover"), where the domain crossover results in a light chain with a VH-CH1 domain sequence and the domain crossover results in a heavy chain fragment with a VL-CL domain sequence (all domain sequences listed above are in the N-terminal to C-terminal direction).
[0285] As used herein, the term "replaced with each other" in relation to corresponding heavy chain domains and light chain domains refers to the above-mentioned domain crossover. Thus, when the CH1 domain and the CL domain are "replaced with each other", the term refers to the domain crossover described under item (i) and the resulting heavy chain and light chain domain sequences. Thus, when the VH and VL are "replaced with each other", the term refers to the domain crossover described under item (ii); and when the CH1 domain and the CL domain are "replaced with each other" and the VH domain and the VL domain are "replaced with each other", the term refers to the domain crossover described under item (iii). Bispecific antibodies containing domain crossovers have been reported, for example, in International Publication Nos. 2009 / 080251, 2009 / 080252, 2009 / 080253, and 2009 / 080254, and Schaefer, W., et al., Proc. Natl. Acad. Sci. USA 108 (2011) 11187-11192. Such antibodies are generally referred to as CrossMabs.
[0286] In one embodiment, the multispecific antibody also comprises at least one Fab fragment comprising either the domain crossover of the CH1 domain and the CL domain described in the above item (i), the domain crossover of the VH and VL domain described in the above item (ii), or the domain crossover of the VH-CH1 and VL-VL domain described in the above item (iii). In the case of a multispecific antibody with domain crossover, Fabs that specifically bind to the same antigen(s) are constructed to have the same domain sequence. Therefore, when two or more Fabs with domain crossovers are contained in a multispecific antibody, the Fab(s) specifically bind to the same antigen.
[0287] A "humanized" antibody refers to an antibody that comprises amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody comprises substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
[0288] The term "recombinant antibody," as used herein, refers to all antibodies (chimeric, humanized, and human) that are prepared, expressed, generated, or isolated by recombinant means, e.g., recombinant cells. This includes, for example, antibodies isolated from recombinant cells such as NS0, HEK, BHK, or CHO cells.
[0289] As used herein, the term "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds, i.e., it is a functional fragment. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, bispecific Fab, diabody, linear antibody, and single-chain antibody molecules (e.g., scFv or scFab).
[0290] As used herein, the term "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds, i.e., it is a functional fragment. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, bispecific Fab, diabody, linear antibody, and single-chain antibody molecules (e.g., scFv or scFab).
[0291] II. Compositions and Methods Typically, recombinant mass production of a polypeptide of interest, such as a therapeutic polypeptide, requires cells that stably express and secrete the polypeptide. These cells are called "recombinant cells" or "recombinant production cells," and the method used to generate such cells is called "cell line development." In the first step of the cell line development method, suitable host cells, such as CHO cells, are transfected with a nucleic acid sequence suitable for expressing the polypeptide of interest. In the second step, cells stably expressing the polypeptide of interest are selected based on the co-expression of a selectable marker that has been co-transfected with the nucleic acid encoding the polypeptide of interest.
[0292] A nucleic acid that encodes a polypeptide, i.e., a coding sequence, is called a structural gene. Such a structural gene is a simple message, and its expression requires additional control elements. Therefore, a structural gene is usually incorporated into an expression cassette. The minimum control elements required for an expression cassette to be functional in mammalian cells are a promoter functional in said mammalian cells located upstream, i.e., 5', of the structural gene, and a polyadenylation signal sequence functional in said mammalian cells located downstream, i.e., 3', of the structural gene. The promoter sequence, structural gene sequence, and polyadenylation signal sequence are arranged in an operably linked form.
[0293] If the polypeptide of interest is a heteromultimeric polypeptide composed of different (monomeric) polypeptides, not only one expression cassette but multiple expression cassettes containing different structural genes are required, i.e., at least one expression cassette for each of the different (monomeric) polypeptides of the heteromultimeric polypeptide. For example, a full-length antibody is a heteromultimeric polypeptide containing two copies of a light chain and two copies of a heavy chain. Thus, a full-length antibody is composed of two different polypeptides. Therefore, two expression cassettes are required for the expression of a full-length antibody: one for the light chain and one for the heavy chain. For example, if the full-length antibody is a bispecific antibody, i.e., the antibody contains two different binding sites that specifically bind to two different antigens, the light chains are different from each other and the heavy chains are different from each other. Thus, such a bispecific full-length antibody is composed of four different polypeptides, and four expression cassettes are required.
[0294] The expression cassette(s) for the polypeptide of interest are in turn incorporated into so-called "expression vectors." An "expression vector" is a nucleic acid that provides all the elements required to amplify said vector in bacterial cells and to express the contained structural gene(s) in mammalian cells. Typically, an expression vector comprises a prokaryotic plasmid propagation unit, which in the case of, for example, E. coli, contains an origin of replication and a prokaryotic or even a eukaryotic selection marker, as well as the expression cassette required for expression of the structural gene(s) of interest. An "expression vector" is a transport vehicle for introducing an expression cassette into mammalian cells.
[0295] As outlined in the previous paragraph, the more complex the polypeptide to be expressed, the greater the number of different expression cassettes required. Essentially, the larger the number of expression cassettes, the larger the size of the nucleic acid to be integrated into the genome of the host cell. At the same time, the size of the expression vector also increases. However, the practical upper limit of vector size is in the range of about 15 kbp, beyond which the efficiency of manipulation and processing decreases significantly. This problem can be addressed by using two or more expression vectors, whereby the expression cassette can be shared between different expression vectors, each containing only a portion of the expression cassette.
[0296] Conventional cell line development (CLD) relies on random integration (RI) of a vector carrying an expression cassette for a polypeptide of interest (SOI). Generally, when a vector is transfected by a random method, some vectors or their fragments are integrated into the cell genome. Therefore, the RI-based transfection process is unpredictable.
[0297] Thus, by addressing the size problem by sharing the expression cassettes among different expression vectors, a new problem arises: the random number of expression cassettes integrated and their spatial distribution.
[0298] Generally, the more expression cassettes for structural gene expression are integrated into the cell genome, the greater the amount of each polypeptide expressed.In addition to the number of expression cassettes integrated, the integration site and locus also affect expression yield.For example, if an expression cassette is integrated into a site with low transcriptional activity in the cell genome, only a small amount of the encoded polypeptide will be expressed.However, if the same expression cassette is integrated into a site with high transcriptional activity in the cell genome, the encoded polypeptide will be expressed in large amounts.
[0299] This difference in expression does not pose a problem as long as the expression cassettes for the different polypeptides of a heteromultimeric polypeptide are all integrated at the same frequency and into loci with similar transcriptional activity, under which circumstances all polypeptides contained in the multimeric polypeptide are expressed in equal amounts and the multimeric polypeptide is assembled correctly.
[0300] However, this scenario is highly unlikely and cannot be guaranteed for molecules composed of more than two polypeptides. For example, International Publication No. 2018 / 162517 discloses that significant differences in expression yield and product quality were observed by RI depending on i) the expression cassette sequence and ii) the distribution of the expression cassettes among different expression vectors. Without being bound by theory, this observation is attributed to the fact that different expression cassettes from different expression vectors are integrated into different loci at different frequencies in cells, resulting in the differential expression of various polypeptides contained in the heteromultimeric polypeptide, i.e., in various, improper ratios. As a result, some monomeric polypeptides are present in relatively high amounts, while others are present in relatively low amounts. This imbalance in the monomers contained in the heteromultimeric polypeptide leads to incomplete assembly, incorrect assembly, and reduced secretion rates. All of the above results in a reduced expression yield of correctly folded heteromultimeric polypeptides and an increased proportion of by-products associated with the product.
[0301] Unlike conventional RI CLD, targeted integration (TI) CLD introduces transgenes containing various expression cassettes into predetermined "hot spots" in the cell genome. Furthermore, this introduction uses a predetermined ratio of the expression cassettes. As a result, without being bound by this theory, all of the various polypeptides contained in the heteromultimeric polypeptide are expressed at the same (or at least similar, with only minor differences) speed and in the appropriate ratio. This should result in an increased amount of correctly assembled heteromultimeric polypeptide, and a decreased rate of by-products associated with the product.
[0302] Also, given a given copy number and a given integration site, recombinant cells obtained by TI should have superior stability compared to cells obtained by RI. Furthermore, because the selection marker is used only to select cells with the appropriate TI and not to select cells showing high levels of transgene expression, a marker with low mutagenicity may be applied to minimize the possibility of generating sequence variants (SVs) due in part to the mutagenicity of selection agents such as methotrexate (MTX) or methionine sulfoximine (MSX).
[0303] II.a Transgenes and Methods According to the Invention Trivalent bispecific antibodies: However, it is now known that the sequence of the expression cassette in the transgene used in TI, i.e., the expression cassette configuration, has a strong influence on trivalent bispecific antibody expression.
[0304] The present invention uses a specific expression cassette configuration with a predetermined number and sequence of individual expression cassettes, which results in high expression yields and good product quality for trivalent bispecific antibodies expressed in mammalian cells.
[0305] The TI method is used for the directed integration of a transgene carrying an expression cassette sequence according to the invention. The present invention provides a novel method for generating recombinant mammalian cells expressing trivalent bispecific antibodies using a two-plasmid recombinase-mediated cassette exchange (RMCE) reaction. The improvement lies in particular in the directed integration at the same locus in the directed sequence, thereby resulting in high expression of the trivalent bispecific antibody and reduced formation of product-related by-products.
[0306] The presently disclosed subject matter provides not only methods for producing recombinant mammalian cells for stable large-scale production of trivalent bispecific antibodies, but also recombinant mammalian cells with high productivity of trivalent bispecific antibodies with advantageous by-product profiles.
[0307] The two-plasmid RMCE strategy used here allows for the insertion of multiple expression cassettes into the same TI locus.
[0308] Recombinant mammalian cells expressing trivalent bispecific antibodies are reported herein. Trivalent bispecific antibodies are heteromultimeric polypeptides that are not naturally expressed by the mammalian cells. More specifically, trivalent bispecific antibodies are heterodimeric proteins consisting of four polypeptides: two different heavy chains and two different light chains. To achieve expression of the trivalent bispecific antibodies, recombinant nucleic acids containing multiple different expression cassettes in specific and predetermined sequences are integrated into the genome of the mammalian cells.
[0309] Also reported herein are methods for making recombinant mammalian cells that express trivalent bispecific antibodies and methods for producing trivalent bispecific antibodies using said recombinant mammalian cells.
[0310] The present invention is based, at least in part, on the discovery that the sequences of different expression cassettes required for expression of heteromultimeric trivalent bispecific antibodies, i.e., expression cassette configuration, affect the expression yield of the trivalent bispecific antibody when integrated into the genome of a mammalian cell.
[0311] The present invention is based, at least in part, on the discovery that dual recombinase-mediated cassette exchange (RMCE) can be used to produce recombinant mammalian cells, such as recombinant CHO cells, whereby a predetermined and specific expression cassette sequence is integrated into the genome, resulting in efficient expression and production of a trivalent bispecific antibody. This integration is induced at a specific site in the genome of the mammalian cell by targeted integration. This makes it possible to control the expression ratio of the different polypeptides of the heteromultimeric antibody relative to each other. This results in efficient expression, accurate assembly, and successful secretion with high expression yields of a correctly folded and assembled trivalent bispecific antibody.
[0312] Because trivalent bispecific antibodies are heterotetramers, their expression requires at least four different expression cassettes: a first expression cassette for the expression of the first heavy chain, a second expression cassette for the expression of the second heavy chain, a third expression cassette for the expression of the first light chain, and a fourth expression cassette for the expression of the second light chain. In addition, an additional expression cassette for a positive selection marker may also be included.
[0313] To investigate the effect of expression cassette configuration on productivity in TI hosts, RMCE pools were generated by transfecting two plasmids (front and back vectors) containing different numbers and arrangements of expression cassettes for the individual chains of a trivalent bispecific antibody with an additional Fab fragment with domain crossover / exchange. After selection, recovery, and validation of RMCEs by flow cytometry, the productivity of the pools was assessed in a 14-day fed-batch production assay.
[0314] The effect of antibody chain expression cassette configuration on the expression of different trivalent bispecific antibodies with additional Fab fragments with domain swapping was evaluated, all with different target specificities.
[0315] It is generally assumed in the art that transient protein expression profiles predict stable expression profiles (see, e.g., Diepenbruck, C., et al. Mol. Biotechnol. 54 (2013) 497-503; Rajendra, Y., et al. Biotechnol. Prog. 33 (2017) 469-477).
[0316] For one BS antibody (BS-1), the following results were obtained from transient transfections (vectors contained only the indicated expression cassettes, vector ratios: l = vector containing one light chain expression cassette; l + h = vector containing one light chain expression cassette and one expression cassette for a heavy chain with a hole mutation; xl + k = vector containing one expression cassette for a light chain with domain swapping and one expression cassette for a heavy chain with a knob mutation; xl = vector containing one expression cassette for a light chain with domain swapping): TIFF2024167256000005.tif69138l=light chain; h=heavy chain with hole mutation; xl=light chain with domain swap; k=heavy chain with knob mutation
[0317] For the first BS antibody and three additional BS antibodies, the following results were obtained for stable targeted integration: TIFF2024167256000006.tif129143MP = main product, eff. titer = effective titer = titer multiplied by the % of the main product
[0318] As can be seen, the results obtained with transient transfection are not predictive in the current case for the transition from transient random integration to stable targeted integration. This can be seen with the k:h:l:xl=2:1:2:3 combination, which is optimal for stable transfection and only third best for transient transfection.
[0319] Antibody BS-1 is an anti-human Aβ / human transferrin receptor trivalent bispecific antibody (SEQ ID NOs: 12 to 15). Antibody BS-3 is an anti-human CD20 / human transferrin receptor trivalent bispecific antibody (SEQ ID NOs: 16 to 19).
[0320] This part of the invention is summarized below.
[0321] One independent aspect of the present invention is a method for producing a trivalent, bispecific antibody, comprising: a) culturing a mammal containing deoxyribonucleic acid encoding a trivalent bispecific antibody; and b) recovering the trivalent bispecific antibody from the cells or culture medium Including, The deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into the genome of a mammalian cell and is arranged in a 5' to 3' direction to contain: a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding a second light chain The method includes:
[0322] Stable integration of deoxyribonucleic acid encoding a trivalent, bispecific antibody into the genome of a mammalian cell can be carried out by any method known to those skilled in the art, as long as the specific sequence of the expression cassette is maintained.
[0323] One independent aspect of the present invention is a method for producing a nucleotide sequence comprising, in the 5' to 3' direction: a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding a second light chain It is a deoxyribonucleic acid comprising:
[0324] One independent aspect of the present invention is a method for producing a nucleotide sequence comprising, in the 5' to 3' direction: a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding a second light chain The present invention relates to the use of a trivalent bispecific antibody in mammalian cells, comprising a deoxyribonucleic acid comprising:
[0325] An independent aspect of the invention is a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent bispecific antibody integrated into the genome of the cell, wherein the deoxyribonucleic acid encoding the trivalent bispecific antibody comprises, in the 5' to 3' direction: a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding a second light chain Includes:
[0326] One independent aspect of the invention is a composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and four expression cassettes, the first deoxyribonucleic acid is, in the 5' to 3' direction, -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, and - a first copy of a third recombination recognition sequence Including, and a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, and a seventh expression cassette encoding a second light chain, and - a second recombination recognition sequence Includes:
[0327] An independent aspect of the invention is a method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent bispecific antibody and that secretes the trivalent bispecific antibody, comprising: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least one first selectable marker, and a third recombination recognition sequence located between the first and second recombination recognition sequences, and wherein the recombination recognition sequences are all different; b) introducing into the cells provided in a) a composition comprising two deoxyribonucleic acids comprising three different recombination recognition sequences and at least seven expression cassettes, - a first deoxyribonucleic acid in the 5' to 3' direction, -first recombination recognition sequence a first expression cassette encoding a first heavy chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the first light chain, a fourth expression cassette encoding a first light chain, and - a first copy of a third recombination recognition sequence Including, and a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, a fifth expression cassette encoding a second heavy chain, a sixth expression cassette encoding either the first light chain or the second heavy chain or the second light chain, a seventh expression cassette encoding a second light chain, and - a second recombination recognition sequence Including, the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the exogenous nucleotide sequence to be integrated; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of the second selection marker; c) i) simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or ii) Then sequentially introducing one or more recombinases into the vector, introducing one or more recombinases that recognize and introduce recombination recognition sequences in the first and second deoxyribonucleic acids (and optionally, the one or more recombinases perform two-recombinase-mediated cassette exchange); and d) selecting cells that express a second selection marker and secrete the trivalent bispecific antibody; This results in a method for producing recombinant mammalian cells that contain deoxyribonucleic acid encoding the trivalent bispecific antibody and that secrete the trivalent bispecific antibody.
[0328] In one embodiment of all independent aspects and all dependent embodiments of the invention, exactly one copy of the deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into a single locus in the genome of the mammalian cell by targeted integration.
[0329] In one embodiment of all independent aspects and all dependent embodiments of the invention, exactly one copy of the deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into a single locus in the genome of the mammalian cell by a single or double recombinase-mediated cassette exchange reaction.
[0330] In one embodiment of every independent aspect and every dependent embodiment of the invention, the deoxyribonucleic acid comprises, after the seven expression cassettes, an eighth expression cassette encoding the second light chain.
[0331] In one embodiment of all independent aspects and dependent embodiments of the invention, the first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain (numbering according to Kabat).
[0332] In one embodiment of every independent aspect and every dependent embodiment of the invention, one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat).
[0333] In one embodiment of all independent aspects and all dependent embodiments of the invention, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment VH-VL or CH1-CL.
[0334] In one embodiment of every independent aspect and every dependent embodiment of the invention, the first light chain is a domain-swapped light chain VH-VL or CH1-CL.
[0335] In one embodiment of all independent aspects and all dependent embodiments of the present invention, the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; The second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site.
[0336] In one embodiment of every independent aspect and every dependent embodiment of the invention, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 12, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 13, the first light chain comprises the amino acid sequence of SEQ ID NO: 14, the second light chain comprises the amino acid sequence of SEQ ID NO: 15, the first binding site specifically binds to the human transferrin receptor, and the second binding site specifically binds to the human Aβ polypeptide.
[0337] In one embodiment of every independent aspect and every dependent embodiment of the invention, the first heavy chain comprises the amino acid sequence of SEQ ID NO: 16, the second heavy chain comprises the amino acid sequence of SEQ ID NO: 17, the first light chain comprises the amino acid sequence of SEQ ID NO: 18, the second light chain comprises the amino acid sequence of SEQ ID NO: 19, the first binding site specifically binds to a human transferrin receptor, and the second binding site specifically binds to a human CD20 polypeptide.
[0338] In one embodiment of every independent aspect and every dependent embodiment of the invention, exactly one copy of the deoxyribonucleic acid is stably integrated into a single site or locus in the genome of the mammalian cell.
[0339] In one embodiment of every independent aspect and every dependent embodiment of the invention, the deoxyribonucleic acid encoding the trivalent, bispecific antibody comprises an additional expression cassette encoding a selectable marker.
[0340] In one embodiment of all independent aspects and all dependent embodiments of the invention, an expression cassette encoding a selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5'-located portion of the expression cassette comprises a promoter and a start codon, and the 3'-located portion of the expression cassette comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence.
[0341] In one embodiment of all independent aspects and all dependent embodiments of the invention, the 5'-located portion of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent upstream to a fourth expression cassette and the start codon is adjacent downstream to a third recombination recognition sequence, and the 3'-located portion of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon, and is adjacent upstream to the third recombination recognition sequence and downstream to a fifth expression cassette, whereby the start codon is operably linked to a coding sequence.
[0342] In one embodiment of all independent aspects and all dependent embodiments of the present invention, each expression cassette for an antibody chain comprises, in 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, and a polyadenylation signal sequence, and optionally, a terminator sequence; and Each expression cassette encoding a selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the selectable marker, and a polyadenylation signal sequence, and optionally, a terminator sequence.
[0343] In one embodiment of all independent aspects and all dependent embodiments of the invention, the promoter is the SV40 promoter, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence, and except for the expression cassette of the selectable marker, which is absent a terminator, the promoter is the human CMV promoter containing intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator.
[0344] Terminator sequences prevent the generation of very long RNA transcripts by RNA polymerase II, i.e., read-through into the next expression cassette in the deoxyribonucleic acid according to the invention, and are used in the method according to the invention, i.e., the expression of one structural gene of interest is controlled by its own promoter.
[0345] Thus, the combination of a polyadenylation signal and a terminator sequence achieves efficient transcription termination. That is, the readthrough of RNA polymerase II is prevented by the presence of a double termination signal. The terminator sequence initiates complex disassembly and promotes dissociation of the RNA polymerase from the DNA template.
[0346] In one embodiment of all independent aspects and all dependent embodiments of the invention, the mammalian cells are CHO cells.
[0347] In one embodiment of all independent aspects and all dependent embodiments of the present invention, all cassettes are arranged in one direction.
[0348] In one embodiment of all independent aspects and all embodiments of the invention, an expression cassette encoding a selectable marker is located partially 5' and partially 3' to a third recombination recognition sequence, the 5'-located portion of the expression cassette comprising a promoter and a start codon, and the 3'-located portion of the expression cassette comprising a coding sequence without a start codon and a polyA signal.
[0349] In one embodiment of all independent aspects and all dependent embodiments of the invention, the 5'-located portion of the expression cassette encoding the selectable marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent to the fourth expression cassette upstream (i.e., located downstream relative to the fourth expression cassette) and the start codon is adjacent to the third recombination recognition sequence downstream (i.e., located upstream of the third recombination recognition sequence), and the 3'-located portion of the expression cassette encoding the selectable marker comprises a nucleic acid encoding a selectable marker lacking a start codon operably linked to a polyadenylation sequence, adjacent to the third recombination recognition sequence upstream and adjacent to the fifth expression cassette downstream.
[0350] In one embodiment of all independent aspects and all dependent embodiments of the invention, the start codon is a translation initiation codon. In one embodiment, the start codon is ATG.
[0351] In one embodiment of every independent aspect and every dependent embodiment of the invention, the first deoxyribonucleic acid is incorporated into a first vector and the second deoxyribonucleic acid is incorporated into a second vector.
[0352] In one embodiment of every independent aspect and every dependent embodiment, each expression cassette comprises, in the 5' to 3' direction, a promoter, a coding sequence, and a polyadenylation signal sequence, optionally followed by a terminator sequence, all operably linked to each other.
[0353] In one embodiment of all independent aspects and all dependent embodiments of the invention, the mammalian cell is a CHO cell. In one embodiment, the CHO cell is a CHO-K1 cell.
[0354] In one embodiment of every independent aspect and every dependent embodiment of the invention, the recombinase recognition sequences are L3, 2L and LoxFas, in one embodiment L3 has the sequence of SEQ ID NO: 01, 2L has the sequence of SEQ ID NO: 02 and LoxFas has the sequence of SEQ ID NO: 03. In one embodiment, the first recombinase recognition sequence is L3, the second recombinase recognition sequence is 2L and the third recombinase recognition sequence is LoxFas.
[0355] In one embodiment of every independent aspect and every dependent embodiment, the promoter is a human CMV promoter including intron A, the polyadenylation signal sequence is a bGH polyA site, and the terminator sequence is an hGT terminator.
[0356] ...
Claims
1. 1. A method for producing a trivalent bispecific antibody, comprising: a) culturing a mammalian cell containing deoxyribonucleic acid encoding said trivalent bispecific antibody; and b) recovering said trivalent bispecific antibody from said cells or culture medium. Including, The deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding said first heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding either said first light chain or said second heavy chain or said second light chain, and - a seventh expression cassette encoding said second light chain A method comprising:
2. A deoxyribonucleic acid encoding a trivalent, bispecific antibody, comprising in the 5' to 3' direction: - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding said first heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding either said first light chain or said second heavy chain or said second light chain, and - a seventh expression cassette encoding said second light chain Deoxyribonucleic acid, including
3. In the 5' to 3' direction, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding said first heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding either said first light chain or said second heavy chain or said second light chain, and - a seventh expression cassette encoding said second light chain 2. Use of a deoxyribonucleic acid comprising the nucleic acid
4. 1. A recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent bispecific antibody integrated into the genome of said cell, said trivalent bispecific antibody-encoding deoxyribonucleic acid comprising, in a 5′ to 3′ direction: - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding said first heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding either said first light chain or said second heavy chain or said second light chain, and - a seventh expression cassette encoding said second light chain A recombinant mammalian cell comprising:
5. A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and four expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding said first heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding said first light chain, and - a first copy of the third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding either said first light chain or said second heavy chain or said second light chain, - a seventh expression cassette encoding said second light chain, and - a second recombination recognition sequence A composition comprising:
6. 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent bispecific antibody and secretes said trivalent bispecific antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least a first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cell provided in a) two compositions of deoxyribonucleic acid comprising three different recombination recognition sequences and at least seven expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding said first heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding said first light chain, and - a first copy of the third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of said third recombination recognition sequence, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding either said first light chain or said second heavy chain or said second light chain, - a seventh expression cassette encoding said second light chain, and - a second recombination recognition sequence Including, the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of said second selection marker; c) i) simultaneously with said first deoxyribonucleic acid and said second deoxyribonucleic acid of b); or ii) Thereafter, sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases which recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); And d) selecting cells that express the second selection marker and secrete the trivalent bispecific antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said trivalent bispecific antibody and that secretes said trivalent bispecific antibody.
7. 7. The method for producing a trivalent bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any one of claims 1 to 6, wherein said deoxyribonucleic acid comprises, after said seventh expression cassette, an eighth expression cassette encoding said second light chain.
8. 8. Method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 1 to 7, wherein the first heavy chain comprises the mutation T366W (numbering according to Kabat) in the CH3 domain and the second heavy chain comprises the mutations T366S, L368A and Y407V (numbering according to Kabat) in the CH3 domain.
9. 9. A method for producing a trivalent bispecific antibody according to claim 8, wherein one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat), or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell.
10. 10. The method for producing a trivalent bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 1 to 9, wherein said first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment VH-VL or CH1-CL.
11. 11. The method for producing a trivalent bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 1 to 10, wherein said first light chain is a domain-swapped light chain VH-VL or CH1-CL.
12. - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; - the second heavy chain comprises, from N-terminus to C-terminus, the first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and - said second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site; A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 1 to 11.
13. 13. A method for producing a trivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 1, 3, 4 and 6 to 12, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus.
14. said deoxyribonucleic acid encoding said trivalent bispecific antibody comprises an additional expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker is located partially 5' and partially 3' to the third recombination recognition sequence, the portion of the expression cassette located 5' comprises a promoter and a start codon, the portion of the expression cassette located 3' comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence; the 5'-located portion of the expression cassette encoding the selection marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is adjacent upstream to the fourth expression cassette and the start codon is adjacent downstream to the third recombination recognition sequence, and the 3'-located portion of the expression cassette encoding the selection marker comprises a nucleic acid encoding a selection marker lacking a start codon, is adjacent upstream to the third recombination recognition sequence and is adjacent downstream to the fifth expression cassette, and the start codon is operably linked to the coding sequence. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 1 to 5 and 7 to 13.
15. each expression cassette for an antibody chain comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, and a polyadenylation signal sequence, and optionally a terminator sequence; and each expression cassette encoding said selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding said selectable marker, and a polyadenylation signal sequence, and optionally a terminator sequence; With the exception of the expression cassette of the selectable marker, wherein the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and a terminator is not present. The promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 1 to 14.
16. 16. The method for producing a trivalent bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 1, 3, 4 and 6 to 15, wherein said mammalian cell is a CHO cell.
17. A method for producing a trivalent bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 1 to 16, wherein all cassettes are arranged in one direction.
18. 1. A method for producing a trivalent antibody, comprising: a) culturing a mammalian cell containing deoxyribonucleic acid encoding the trivalent antibody; and b) recovering the trivalent antibody from the cells or culture medium. Including, The deoxyribonucleic acid encoding the trivalent antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, and - a fifth expression cassette encoding a second light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, or (3) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second light chain, or (4) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said first heavy chain, - a sixth expression cassette encoding said second light chain, or (5) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second heavy chain, - a sixth expression cassette encoding said second light chain, - a seventh expression cassette encoding said second light chain, or (6) - a first expression cassette encoding a first light chain, - a second expression cassette encoding said first light chain, - a third expression cassette encoding the first heavy chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain A method comprising any one of the steps of:
19. A deoxyribonucleic acid encoding a trivalent antibody, comprising in the 5' to 3' direction: (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, and - a fifth expression cassette encoding a second light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, or (3) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second light chain, or (4) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said first heavy chain, - a sixth expression cassette encoding said second light chain, or (5) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second heavy chain, - a sixth expression cassette encoding said second light chain, - a seventh expression cassette encoding said second light chain, or (6) - a first expression cassette encoding a first light chain, - a second expression cassette encoding said first light chain, - a third expression cassette encoding the first heavy chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain Deoxyribonucleic acid, including any one of the following:
20. In the 5' to 3' direction, (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, and - a fifth expression cassette encoding a second light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, or (3) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second light chain, or (4) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said first heavy chain, - a sixth expression cassette encoding said second light chain, or (5) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second heavy chain, - a sixth expression cassette encoding said second light chain, - a seventh expression cassette encoding said second light chain, or (6) - a first expression cassette encoding a first light chain, - a second expression cassette encoding said first light chain, - a third expression cassette encoding the first heavy chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain 2. Use of a deoxyribonucleic acid comprising any one of the above for expressing a trivalent antibody in a mammalian cell.
21. 1. A recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody integrated into the genome of said cell, said trivalent antibody-encoding deoxyribonucleic acid comprising, in a 5′ to 3′ direction: (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, and - a fifth expression cassette encoding a second light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, or (3) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second light chain, or (4) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said first heavy chain, - a sixth expression cassette encoding said second light chain, or (5) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, - a fifth expression cassette encoding said second heavy chain, - a sixth expression cassette encoding said second light chain, - a seventh expression cassette encoding said second light chain, or (6) - a first expression cassette encoding a first light chain, - a second expression cassette encoding said first light chain, - a third expression cassette encoding the first heavy chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain A recombinant mammalian cell comprising any one of the above.
22. A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and five to seven expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, (1) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (3) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (4) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (5) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (6) - a first recombination recognition sequence, - a first expression cassette encoding a first light chain, - a second expression cassette encoding said first light chain, - a third expression cassette encoding the first heavy chain, and - a first copy of the third recombination recognition sequence Including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, and - a second recombination recognition sequence, or (3) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (4) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding the first heavy chain, - a sixth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (5) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding a second light chain, - a seventh expression cassette encoding said second light chain, and - a second recombination recognition sequence, or (6) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, and - a second recombination recognition sequence A composition comprising any one of the following:
23. 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a trivalent antibody and secretes said trivalent antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least a first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cell provided in a) two compositions of deoxyribonucleic acid comprising three different recombination recognition sequences and 5 to 7 expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, (1) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (3) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (4) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (5) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of a third recombination recognition sequence, or (6) - a first recombination recognition sequence, - a first expression cassette encoding a first light chain, - a second expression cassette encoding said first light chain, - a third expression cassette encoding the first heavy chain, and - a first copy of the third recombination recognition sequence Including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, and - a second recombination recognition sequence, or (3) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (4) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding the first heavy chain, - a sixth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (5) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding a second light chain, - a seventh expression cassette encoding said second light chain, and - a second recombination recognition sequence, or (6) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding a second light chain, - a sixth expression cassette encoding said second light chain, and - a second recombination recognition sequence Including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of said second selection marker; c) i) simultaneously with said first deoxyribonucleic acid and said second deoxyribonucleic acid of b); or ii) Thereafter, sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases which recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); And d) selecting cells that express the second selection marker and secrete the trivalent antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said trivalent antibody and that secretes said trivalent antibody.
24. 24. A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 18 to 23, wherein the first heavy chain comprises the mutation T366W (numbering according to Kabat) in the CH3 domain and the second heavy chain comprises the mutations T366S, L368A and Y407V (numbering according to Kabat) in the CH3 domain, or vice versa.
25. 25. A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to claim 24, wherein one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat).
26. 26. The method for producing a trivalent antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 18 to 25, wherein the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment.
27. 27. The method for producing a trivalent antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 18 to 26, wherein said first light chain is a domain-swapped light chain VH-VL or CH1-CL.
28. - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the second heavy chain comprises, from N-terminus to C-terminus, the first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - said first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; - said second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 18 to 27.
29. 29. A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 18, 20, 21 and 23 to 28, wherein said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus.
30. 30. A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell according to any one of claims 18 to 22 and 24 to 29, wherein the deoxyribonucleic acid encoding the trivalent antibody comprises a further expression cassette encoding a selection marker, the expression cassette encoding the selection marker being located partially 5' and partially 3' to the third recombination recognition sequence, the part of the expression cassette located 5' comprises a promoter and a start codon, the part of the expression cassette located 3' comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence.
31. With the exception of the expression cassette of the selectable marker, wherein the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and a terminator is not present. The promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator. A method for producing a trivalent antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 18 to 22 and 24 to 30.
32. 32. The method for producing a trivalent antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 18, 20, 21 and 23 to 31, wherein said mammalian cell is a CHO cell.
33. 33. The method for producing a trivalent antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 18 to 32, wherein when the 5' to 3' configuration has as the first expression cassette an expression cassette encoding the first heavy chain, all cassettes are arranged in one direction.
34. 33. The method for producing a trivalent antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any one of claims 17 to 32, wherein when the 5' to 3' configuration is a first expression cassette encoding the first light chain, a second expression cassette encoding the first light chain, a third expression cassette encoding the first heavy chain, a fourth expression cassette encoding the second heavy chain, a fifth expression cassette encoding the second light chain, and a sixth expression cassette encoding the second light chain, the first expression cassette to the third expression cassette are arranged in one direction and the fourth expression cassette to the sixth expression cassette are arranged in one direction, whereby the first expression cassette to the third expression cassette are arranged in the opposite direction to the fourth expression cassette to the sixth expression cassette.
35. 1. A method for producing a bivalent, bispecific antibody, comprising: a) culturing a mammalian cell comprising deoxyribonucleic acid encoding said bivalent, bispecific antibody; and b) recovering said bivalent, bispecific antibody from said cells or culture medium. Including, The deoxyribonucleic acid encoding the bivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: - a first expression cassette encoding a first light chain, - a second expression cassette encoding the first heavy chain, - a third expression cassette encoding a second light chain, and - a fourth expression cassette encoding a second heavy chain Including, wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat).
36. A deoxyribonucleic acid encoding a bivalent, bispecific antibody, comprising, in the 5' to 3' direction: - a first expression cassette encoding a first light chain, - a second expression cassette encoding the first heavy chain, - a third expression cassette encoding a second light chain, and - a fourth expression cassette encoding a second heavy chain Including, A deoxyribonucleic acid, wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat).
37. In the 5' to 3' direction, - a first expression cassette encoding a first light chain, - a second expression cassette encoding the first heavy chain, - a third expression cassette encoding a second light chain, and - a fourth expression cassette encoding a second heavy chain for the expression in a mammalian cell of a bivalent, bispecific antibody, comprising 1. Use wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat).
38. 1. A recombinant mammalian cell comprising a bivalent, bispecific antibody-encoding deoxyribonucleic acid integrated into the genome of said cell, said bivalent, bispecific antibody-encoding deoxyribonucleic acid comprising, in a 5′ to 3′ direction: - a first expression cassette encoding a first light chain, - a second expression cassette encoding the first heavy chain, - a third expression cassette encoding a second light chain, and - a fourth expression cassette encoding a second heavy chain Including, 1. A recombinant mammalian cell, wherein said first heavy chain comprises the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprises the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat).
39. A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and four expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, - a first recombination recognition sequence, - a first expression cassette encoding a first light chain, - a second expression cassette encoding the first heavy chain, and - a first copy of the third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, - a third expression cassette encoding a second light chain, - a fourth expression cassette encoding a second heavy chain, and - a second recombination recognition sequence Including, said first heavy chain comprising the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprising the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat).
40. 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a bivalent, bispecific antibody and secretes said bivalent, bispecific antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least a first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cell provided in a) two compositions of deoxyribonucleic acid comprising three different recombination recognition sequences and four expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, - a first recombination recognition sequence, - a first expression cassette encoding a first light chain, - a second expression cassette encoding the first heavy chain, and - a first copy of the third recombination recognition sequence Including, and, a second deoxyribonucleic acid in the 5' to 3' direction, - a second copy of a third recombination recognition sequence, - a third expression cassette encoding a second light chain, - a fourth expression cassette encoding a second heavy chain, and - a second recombination recognition sequence Including, the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; the 5'-end portion and the 3'-end portion of an expression cassette encoding a second selection marker, when taken together, form a functional expression cassette of said second selection marker, introducing, said first heavy chain comprising the mutation T366W in the CH3 domain (numbering according to Kabat) and said second heavy chain comprising the mutations T366S, L368A, and Y407V in the CH3 domain (numbering according to Kabat), c) i) simultaneously with said first deoxyribonucleic acid and said second deoxyribonucleic acid of b); or ii) Thereafter, sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases which recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); And d) selecting cells that express the second selection marker and secrete the bivalent, bispecific antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said bivalent, bispecific antibody and that secretes said bivalent, bispecific antibody.
41. 41. A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 35 to 40, wherein one of the heavy chains further comprises the mutation S354C and the respective other heavy chain comprises the mutation Y349C (numbering according to Kabat).
42. 42. The method for producing a bivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 35 to 41, wherein said second light chain is the domain-swapped light chain VH-CH1 after VH-VL swapping, or the domain-swapped light chain VL-CH1 after CH1-CL swapping.
43. - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the second heavy chain comprises, from N-terminus to C-terminus, the first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - said first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; - said second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 35 to 42.
44. 44. A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 35, 37, 38 and 40 to 43, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus.
45. wherein the deoxyribonucleic acid encoding the bivalent, bispecific antibody comprises a further expression cassette encoding a selection marker, the expression cassette encoding the selection marker being located partially 5' and partially 3' to the third recombination recognition sequence, the portion of the expression cassette located at 5' comprises a promoter and a start codon, the portion of the expression cassette located at 3' comprises a coding sequence without a start codon and a polyA signal, the start codon being operably linked to the coding sequence, and the portion of the expression cassette located at 5' encoding the selection marker comprises a promoter sequence operably linked to a start codon, whereby 45. The method for producing a bivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any one of claims 35 to 39 and 40 to 44, wherein the promoter sequence is adjacent to the second expression cassette upstream and the start codon is adjacent to the third recombination recognition sequence downstream, and the 3' located portion of the expression cassette encoding the selection marker comprises a nucleic acid encoding a selection marker lacking a start codon, adjacent to the third recombination recognition sequence upstream and adjacent to the third expression cassette downstream, and the start codon is operably linked to the coding sequence.
46. each expression cassette for an antibody chain comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, a polyadenylation signal sequence, and optionally a terminator sequence; and each expression cassette encoding said selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding said selectable marker, and a polyadenylation signal sequence, and optionally a terminator sequence; With the exception of the expression cassette of the selectable marker, wherein the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and a terminator is not present. The promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator. A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 35 to 45.
47. 47. The method for producing a bivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 35, 37, 38 and 40 to 46, wherein said mammalian cell is a CHO cell.
48. A method for producing a bivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 35 to 47, wherein all cassettes are arranged in one direction.
49. 1. A method for producing a multivalent, bispecific antibody, comprising: a) culturing a mammalian cell containing deoxyribonucleic acid encoding said multivalent, bispecific antibody; and b) recovering the multivalent, bispecific antibody from the cells or culture medium. Including, The deoxyribonucleic acid encoding the multivalent, bispecific antibody is stably integrated into the genome of the mammalian cell and comprises, in a 5' to 3' direction: (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding said first light chain, and - a sixth expression cassette encoding said first light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding said first light chain, - a seventh expression cassette encoding said first light chain, and an eighth expression cassette encoding said first light chain A method comprising any one of the steps of:
50. A deoxyribonucleic acid encoding a multivalent, bispecific antibody, comprising, in the 5' to 3' direction: (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding said first light chain, and - a sixth expression cassette encoding said first light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding said first light chain, - a seventh expression cassette encoding said first light chain, and an eighth expression cassette encoding said first light chain Deoxyribonucleic acid, including any one of the following:
51. In the 5' to 3' direction, (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding said first light chain, and - a sixth expression cassette encoding said first light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding said first light chain, - a seventh expression cassette encoding said first light chain, and an eighth expression cassette encoding said first light chain 2. Use of a deoxyribonucleic acid comprising any one of the above for expressing a multivalent bispecific antibody in a mammalian cell.
52. 1. A recombinant mammalian cell comprising a multivalent, bispecific antibody-encoding deoxyribonucleic acid integrated into the genome of said cell, said multivalent, bispecific antibody-encoding deoxyribonucleic acid comprising, in a 5′ to 3′ direction: (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding said first light chain, and - a sixth expression cassette encoding said first light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding said first light chain, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding said first light chain, - a seventh expression cassette encoding said first light chain, and an eighth expression cassette encoding said first light chain A recombinant mammalian cell comprising any one of the above.
53. A composition comprising two deoxyribonucleic acids, which in turn comprise three different recombination recognition sequences and six or eight expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, (1) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding said first light chain, and - a first copy of the third recombination recognition sequence Including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding the first light chain, - a sixth expression cassette encoding said first light chain, and - a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding the first light chain, - a seventh expression cassette encoding said first light chain, - an eighth expression cassette encoding said first light chain, and - a second recombination recognition sequence A composition comprising any one of the following:
54. 1. A method for producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding a multivalent, bispecific antibody and secretes said multivalent, bispecific antibody, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least a first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and wherein said recombination recognition sequences are all different; b) introducing into the cell provided in a) two compositions of deoxyribonucleic acid comprising three different recombination recognition sequences and six or eight expression cassettes, a first deoxyribonucleic acid in the 5' to 3' direction, (1) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, and - a first copy of a third recombination recognition sequence, or (2) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding the first light chain, - a third expression cassette encoding said first light chain, - a fourth expression cassette encoding said first light chain, and - a first copy of the third recombination recognition sequence Including any of the following: and, a second deoxyribonucleic acid in the 5' to 3' direction, (1) - a second copy of a third recombination recognition sequence, - a fourth expression cassette encoding a second heavy chain, - a fifth expression cassette encoding the first light chain, - a sixth expression cassette encoding said first light chain, and - a second recombination recognition sequence, or (2) - a second copy of a third recombination recognition sequence, - a fifth expression cassette encoding a second heavy chain, - a sixth expression cassette encoding the first light chain, - a seventh expression cassette encoding said first light chain, - an eighth expression cassette encoding said first light chain, and - a second recombination recognition sequence Including any of the following: the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; introducing a 5'-end portion and a 3'-end portion of an expression cassette encoding a second selection marker, which, when taken together, form a functional expression cassette of said second selection marker; c) i) simultaneously with said first deoxyribonucleic acid and said second deoxyribonucleic acid of b); or ii) Thereafter, sequentially introducing one or more recombinases into the vector, introducing said one or more recombinases which recognize said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); And d) selecting cells that express the second selection marker and secrete the multivalent, bispecific antibody. thereby producing a recombinant mammalian cell that contains deoxyribonucleic acid encoding said multivalent bispecific antibody and that secretes said multivalent bispecific antibody.
55. 55. Method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 49 to 54, wherein said first heavy chain comprises the mutation T366W (numbering according to Kabat) in the CH3 domain and said second heavy chain comprises the mutations T366S, L368A and Y407V (numbering according to Kabat) in the CH3 domain, or vice versa.
56. 56. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to claim 55, wherein one of the heavy chains further comprises the mutation S354C and each other heavy chain comprises the mutation Y349C (numbering according to Kabat).
57. 57. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 49 to 56, wherein said first light chain is a domain-swapped light chain VH-VL or CH1-CL.
58. - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a first light chain variable domain; - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, and a second heavy chain variable domain; and - said first light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; A method for producing a multivalent, bispecific antibody according to any one of claims 49 to 57, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell.
59. 59. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 49, 51, 52 and 54 to 58, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus.
60. The deoxyribonucleic acid encoding the multivalent, bispecific antibody comprises a further expression cassette encoding a selection marker, the expression cassette encoding the selection marker being located partially 5' and partially 3' to the third recombination recognition sequence, the portion of the expression cassette located at 5' comprises a promoter and a start codon, the portion of the expression cassette located at 3' comprises a coding sequence without a start codon and a polyA signal, the start codon being operably linked to the coding sequence, the portion of the expression cassette located at 5' encoding the selection marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is upstream of the 60. The method for producing a multivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell according to any one of claims 49 to 53 and 55 to 59, wherein the 3'-located portion of the expression cassette encoding the selection marker comprises a nucleic acid encoding a selection marker lacking a start codon, and is adjacent to the third recombination recognition sequence upstream and adjacent to the fourth expression cassette or the fifth expression cassette, respectively, and wherein the start codon is operably linked to the coding sequence.
61. each expression cassette for an antibody chain comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding the antibody chain, and a polyadenylation signal sequence, and optionally a terminator sequence; and each expression cassette encoding said selectable marker comprises, in the 5' to 3' direction, a promoter, a nucleic acid encoding said selectable marker, and a polyadenylation signal sequence, and optionally a terminator sequence; With the exception of the expression cassette of the selectable marker, wherein the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and a terminator is not present. The promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 49 to 60.
62. 62. The method for producing a multivalent, bispecific antibody, or the deoxyribonucleic acid, or the use, or the recombinant mammalian cell, or the composition, or the method for producing a recombinant mammalian cell, according to any one of claims 49, 51, 52 and 54 to 61, wherein said mammalian cell is a CHO cell.
63. 63. A method for producing a multivalent, bispecific antibody, or a deoxyribonucleic acid, or a use, or a recombinant mammalian cell, or a composition, or a method for producing a recombinant mammalian cell, according to any one of claims 49 to 62, wherein all expression cassettes are arranged in one direction.
64. 1. A method for producing a recombinant mammalian cell that contains a deoxyribonucleic acid encoding a polypeptide and secretes said polypeptide, comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a genomic locus of said mammalian cell, said exogenous nucleotide sequence comprising a first recombination recognition sequence and a second recombination recognition sequence adjacent to at least a first selectable marker, and a third recombination recognition sequence located between said first recombination recognition sequence and said second recombination recognition sequence, and said recombination recognition sequences are all different, and said mammalian cell does not comprise DNA encoding Cre recombinase; b) introducing into the cell provided in a) two compositions of deoxyribonucleic acid comprising three different recombination recognition sequences and one to eight expression cassettes, the first deoxyribonucleic acid comprises, in the 5' to 3' direction: - a first recombination recognition sequence, - one or more expression cassettes, - the 5' end portion of an expression cassette encoding a second selection marker, and - a first copy of the third recombination recognition sequence Including, and, a second deoxyribonucleic acid having in the 5' to 3' direction - a second copy of a third recombination recognition sequence, - a 3'-end portion of said expression cassette encoding a second selection marker, - one or more expression cassettes, and - a second recombination recognition sequence Includes the first recombination recognition sequence to the third recombination recognition sequence of the first deoxyribonucleic acid and the second deoxyribonucleic acid correspond to the first recombination recognition sequence to the third recombination recognition sequence of the integrated exogenous nucleotide sequence; the 5'-end portion and the 3'-end portion of the expression cassette encoding said one second selection marker, when taken together, form a functional expression cassette of said one second selection marker, introducing, wherein the deoxyribonucleic acid does not contain DNA encoding Cre recombinase; c) i) simultaneously with said first deoxyribonucleic acid and said second deoxyribonucleic acid of b); or ii) Thereafter, sequentially Introducing Cre recombinase mRNA as the sole source of Cre recombinase, introducing said Cre recombinase, which recognizes said recombination recognition sequences of said first deoxyribonucleic acid and said second deoxyribonucleic acid (and optionally said one or more recombinases perform two-recombinase-mediated cassette exchange); And d) selecting cells which express the second selection marker and secrete the polypeptide. thereby producing a recombinant mammalian cell which contains a deoxyribonucleic acid encoding said polypeptide and which secretes said polypeptide.
65. 65. The method of claim 64, wherein the Cre mRNA encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:
20.
66. 65. The method of claim 64, wherein the Cre mRNA comprises the nucleotide sequence of SEQ ID NO: 21 or a codon usage optimized variant thereof.
67. 67. The method of any one of claims 64 to 66, wherein exactly one copy of said deoxyribonucleic acid is stably integrated into the genome of said mammalian cell at a single site or locus.
68. said deoxyribonucleic acid encoding said polypeptide comprises at least four expression cassettes; - a first recombination recognition sequence is located 5' to the most 5' (i.e. first) expression cassette, - a second recombination recognition sequence is located 3' to the 3'-most expression cassette, a third recombination recognition sequence, - between said first recombination recognition sequence and said second recombination recognition sequence, and - between two of said expression cassettes Located in and The recombination recognition sequences are all different.
68. The method according to any one of claims 64 to 67.
69. The method according to any one of claims 64 to 68, wherein said deoxyribonucleic acid encoding said polypeptide comprises an additional expression cassette encoding a selectable marker.
70. 70. The method of any one of claims 64 to 69, wherein the deoxyribonucleic acid encoding the polypeptide comprises a further expression cassette encoding a selectable marker, the expression cassette encoding the selectable marker being located partially 5' and partially 3' to the third recombination recognition sequence, the portion of the expression cassette located 5' comprises a promoter and a start codon, the portion of the expression cassette located 3' comprises a coding sequence without a start codon and a polyA signal, and the start codon is operably linked to the coding sequence.
71. The method according to any one of claims 64 to 70, wherein the weight ratio of Cre mRNA to the mixture of the first vector and the second vector is within the range of 1:3 to 2:
1.
72. The method of any one of claims 64 to 71, wherein the weight ratio of Cre mRNA to the mixture of the first vector and the second vector is about 1:
5.
73. each of said expression cassettes comprises, in the 5' to 3' direction, a promoter, a coding sequence, and a polyadenylation signal sequence, optionally followed by a terminator sequence; With the exception of the expression cassette of the selectable marker, wherein the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and a terminator is not present. The promoter is a human CMV promoter containing intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator.
73. The method according to any one of claims 64 to 72.
74. 74. The method of any one of claims 64 to 73, wherein the mammalian cell is a CHO cell.
75. the polypeptide is a heterotetramer comprising a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain, and the deoxyribonucleic acid comprises four expression cassettes; - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - said second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - said first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; and - said second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; 75. The method according to any one of claims 64 to 74.
76. the polypeptide is a heterotetramer comprising a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain, the deoxyribonucleic acid comprising four expression cassettes; and - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - said second heavy chain comprises, from N-terminus to C-terminus, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - said first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain; and - said second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; 75. The method according to any one of claims 64 to 74.
77. the polypeptide is a heterotetramer comprising a first antibody heavy chain, a second antibody heavy chain, a first antibody light chain, and a second antibody light chain, and the deoxyribonucleic acid comprises four expression cassettes; - said first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, a peptide linker, a second heavy chain variable domain, and a CL domain; - said second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain; - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain; and - said second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain; the second heavy chain variable domain and the first light chain variable domain form a first binding site, and the first heavy chain variable domain and the second light chain variable domain form a second binding site; 75. The method according to any one of claims 64 to 74.
78. The method of any one of claims 64 to 77, wherein the first recombinase recognition sequence is L3, the second recombinase recognition sequence is 2L, and the third recombinase recognition sequence is LoxFas.
79. Use of Cre-recombinase mRNA to increase the number of recombinant mammalian cells which contain a deoxyribonucleic acid encoding a polypeptide or protein of interest which is stably integrated into a single site in the genome of said recombinant mammalian cells by targeted integration.
80. 80. The use of claim 79, wherein the recombinant cell further secretes the polypeptide of interest into a culture medium when cultured in the culture medium.
Citation Information
Patent Citations
Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
WO2006007850A1
A novel process and reagent for rapid genetic alterations in eukaryotic cells
WO2013006142A1
Blood brain barrier shuttle
WO2014033074A1
T cell activating bispecific antigen binding molecules agiant FOLR1 and CD3
WO2016079076A1
Bispecific antibodies with tetravalency for a costimulatory TNF receptor
WO2017060144A1
